U.S. patent application number 14/208319 was filed with the patent office on 2014-08-21 for modulators of cystic fibrosis transmembrane conductance regulator vpi.
This patent application is currently assigned to VERTEX PHARMACEUTICALS INCORPORATED. The applicant listed for this patent is VERTEX PHARMACEUTICALS INCORPORATED. Invention is credited to Hayley Binch, Peter D.J. Grootenhuis, Sara Hadida Ruah, Jinglan Zhou.
Application Number | 20140235668 14/208319 |
Document ID | / |
Family ID | 39798146 |
Filed Date | 2014-08-21 |
United States Patent
Application |
20140235668 |
Kind Code |
A1 |
Binch; Hayley ; et
al. |
August 21, 2014 |
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
VPI
Abstract
The present invention relates to modulators of ATP-Binding
Cassette ("ABC") transporters or fragments thereof, including
Cystic Fibrosis Transmembrane Conductance Regulator, compositions
thereof, and methods therewith. The present invention also relates
to methods of treating ABC transporter mediated diseases using such
modulators.
Inventors: |
Binch; Hayley; (Encinitas,
CA) ; Grootenhuis; Peter D.J.; (San Diego, CA)
; Hadida Ruah; Sara; (La Jolla, CA) ; Zhou;
Jinglan; (San Diego, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
VERTEX PHARMACEUTICALS INCORPORATED |
BOSTON |
MA |
US |
|
|
Assignee: |
VERTEX PHARMACEUTICALS
INCORPORATED
BOSTON
MA
|
Family ID: |
39798146 |
Appl. No.: |
14/208319 |
Filed: |
March 13, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13750400 |
Jan 25, 2013 |
8710075 |
|
|
14208319 |
|
|
|
|
12623626 |
Nov 23, 2009 |
8399479 |
|
|
13750400 |
|
|
|
|
PCT/US08/64646 |
May 23, 2008 |
|
|
|
12623626 |
|
|
|
|
60968704 |
Aug 29, 2007 |
|
|
|
60931775 |
May 25, 2007 |
|
|
|
Current U.S.
Class: |
514/301 ;
435/375 |
Current CPC
Class: |
A61P 19/00 20180101;
A61P 25/14 20180101; A61P 7/02 20180101; A61P 21/00 20180101; A61P
3/06 20180101; A61P 25/28 20180101; A61P 5/14 20180101; A61K
31/4365 20130101; A61P 13/12 20180101; A61P 25/00 20180101; A61P
7/00 20180101; A61P 25/16 20180101; A61P 35/00 20180101; A61P 37/00
20180101; C07D 495/04 20130101; A61P 5/16 20180101; A61P 3/10
20180101; A61P 7/04 20180101; A61P 11/00 20180101; A61P 43/00
20180101 |
Class at
Publication: |
514/301 ;
435/375 |
International
Class: |
C07D 495/04 20060101
C07D495/04 |
Claims
1-34. (canceled)
35. A method of modulating CFTR activity comprising the step of
contacting said CFTR with a compound of formula I: ##STR00058## or
a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 is a
5-6 membered aromatic monocyclic ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, wherein
said ring is optionally fused to a 5-12 membered monocyclic or
bicyclic, aromatic, partially unsaturated, or saturated ring,
wherein each ring contains 0-4 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein Ar.sup.1 has m
substituents, each independently selected from --WR.sup.W; W is a
bond or is an optionally substituted C.sub.1-C.sub.6 alkylidene
chain wherein up to two methylene units of W are optionally and
independently replaced by O, --CO--, --CS--, --COCO--, --CONR'--,
--CONR'NR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--,
--NR'CONR'--, --C(O)NR'--, --OCONR'--, --NR'NR', --NR'NR'CO--,
--NR'CO--, --S--, --SO, --SO.sub.2--, --NR'--, --SO.sub.2NR'--,
NR'SO.sub.2--, or --NR'SO.sub.2NR'--; R.sup.W is independently R',
halo, cyano, CF.sub.3, CHF.sub.2, OCHF.sub.2, Me, Et, CH(Me).sub.2,
CHMeEt, n-propyl, t-butyl, OH, OMe, OEt, OPh, O-fluorophenyl,
O-difluorophenyl, O-methoxyphenyl, O-tolyl, O-benzyl, SMe,
SCF.sub.3, SCHF.sub.2, SEt, CH.sub.2CN, NH.sub.2, NHMe,
N(Me).sub.2, NHEt, N(Et).sub.2, C(O)CH.sub.3, C(O)Ph, C(O)NH.sub.2,
SPh, SO.sub.2-(amino-pyridyl), SO.sub.2NH.sub.2, SO.sub.2Ph,
SO.sub.2NHPh, SO.sub.2--N-morpholino, SO.sub.2--N-pyrrolidyl,
N-pyrrolyl, N-morpholino, 1-piperidyl, phenyl, benzyl,
(cyclohexyl-methylamino)methyl,
4-Methyl-2,4-dihydro-pyrazol-3-one-2-yl, benzimidazol-2yl,
furan-2-yl, 4-methyl-4H-[1,2,4]triazol-3-yl,
3-(4'-chlorophenyl)-[1,2,4]oxadiazol-5-yl, NHC(O)Me, NHC(O)Et,
NHC(O)Ph, or NHSO.sub.2Me; m is 0-5; k is 0-2; each of R.sup.1 is
independently --X--R.sup.X; X is a bond or is an optionally
substituted C.sub.1-C.sub.6 alkylidene chain wherein up to two
methylene units of X are optionally and independently replaced by
--CO--, --CS--, --COCO--, --CONR'--, --CONR'NR'--, --CO.sub.2--,
--OCO--, --NR'CO.sub.2--, --O--, --NR'CONR'--, --NR'NR',
--NR'NR'CO--, --NR'CO--, --S--, --SO, --SO.sub.2--, NR'SO.sub.2--,
or --NR'SO.sub.2NR'--; R.sup.X is independently R', halo, NO.sub.2,
CN, CF.sub.3, or OCF.sub.3; R.sup.2 is hydrogen; R.sup.3 is
hydrogen; R.sup.4 is hydrogen or a C.sub.1-6 aliphatic group
optionally substituted with --X--R.sup.X; R' is independently
selected from hydrogen or an optionally substituted group selected
from a C.sub.1-C.sub.8 aliphatic group, a 3-8-membered saturated,
partially unsaturated, or fully unsaturated monocyclic ring having
0-3 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an 8-12 membered saturated, partially unsaturated, or
fully unsaturated bicyclic ring system having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; or two
occurrences of R' are taken together with the atom(s) to which they
are bound to form an optionally substituted 3-12 membered
saturated, partially unsaturated, or fully unsaturated monocyclic
or bicyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.
36. A method of treating or lessening the severity of a disease in
a patient, wherein said disease is selected from cystic fibrosis,
hereditary emphysema, COPD, or dry-eye disease, said method
comprising the step of administering to said patient an effective
amount of a compound of formula I according to claim 35.
37-38. (canceled)
39. The method according to claim 35, wherein Ar.sup.1 is selected
from: ##STR00059## wherein ring A.sub.1 5-6 membered aromatic
monocyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur; or A.sub.1 and A.sub.2, together, is
an 8-14 membered aromatic, bicyclic or tricyclic aromatic ring,
wherein each ring contains 0-4 heteroatoms independently selected
from nitrogen, oxygen, or sulfur.
40. The method according to claim 39, wherein A.sub.1 is an
optionally substituted 6 membered aromatic ring having 0-4
heteroatoms, wherein said heteroatom is nitrogen.
41. The method according to claim 39, wherein A.sub.1 is an
optionally substituted phenyl.
42. The method according to claim 39, wherein A.sub.2 is an
optionally substituted 6 membered aromatic ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
43. The method according to claim 39, wherein A.sub.2 is an
optionally substituted 5-membered aromatic ring having 0-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
44. The method according to claim 39, wherein A.sub.2 is a
5-membered aromatic ring having 1-2 nitrogen atoms.
45. The method according to claim 39, wherein A.sub.2 is selected
from: ##STR00060## ##STR00061## ##STR00062## wherein ring A.sub.2
is fused to ring A.sub.1 through two adjacent ring atoms.
46. The method according to claim 35, wherein R.sup.2 and R.sup.4
is hydrogen.
47. The method according to claim 46, wherein R.sup.1 is
hydrogen.
48. The method according to claim 39, wherein said compound has
formula IIA, or formula IIB: ##STR00063##
49. The method according to claim 39, wherein said compound has
formula IIIA, formula, formula IIIB, formula IIIC, formula IIID, or
formula IIIE: ##STR00064## wherein: each of X.sub.1, X.sub.2,
X.sub.3, X.sub.4, and X.sub.5 is independently selected from CH or
N; and X.sub.6 is O, S, or NR'.
50. The method according to claim 49, wherein each of X.sub.1,
X.sub.2, X.sub.3, X.sub.4, and X.sub.5 in formula IIIA is CH.
51. The method according to claim 49, wherein X.sub.1, X.sub.2,
X.sub.3, X.sub.4, and X.sub.5 taken together in compound of formula
IIIA is an optionally substituted ring selected from pyridyl,
pyrazinyl, or pyrimidinyl.
52. The method according to claim 49 wherein X.sub.1, X.sub.2,
X.sub.3, or X.sub.5, taken together with ring A.sub.2 in compounds
of formula IIIB, formula IIIC, or formula IIID, is an optionally
substituted ring selected from: ##STR00065## ##STR00066##
##STR00067## ##STR00068## ##STR00069## ##STR00070##
##STR00071##
53. The method according to claim 39, wherein said compound has
formula IVA, formula IVB, or formula IVC: ##STR00072##
54. The method according to claim 53, wherein ring A.sub.2 is an
optionally substituted, saturated, unsaturated, or aromatic 5-7
membered ring with 0-3 heteroatoms selected from O, S, or N.
55. The method according to claim 53, wherein said compound has
formula VA-1: ##STR00073## wherein each of WR.sup.W2 and WR.sup.W4
is independently selected from hydrogen, CN, CF.sub.3, OCF.sub.3,
halo, C1-C6 straight or branched alkyl, 3-12 membered
cycloaliphatic, phenyl, C5-C10 heteroaryl or C3-C7 heterocyclic,
wherein said heteroaryl or heterocyclic has up to 3 heteroatoms
selected from O, S, or N, wherein said WR.sup.W2 and WR.sup.W4 is
independently and optionally substituted with up to three
substituents selected from --OR', --CF.sub.3, --OCF.sub.3, SR',
S(O)R', SO.sub.2R', --SCF.sub.3, halo, CN, --COOR', --COR',
--O(CH.sub.2).sub.2N(R')(R'), --O(CH.sub.2)N(R')(R'),
--CON(R')(R'), --(CH.sub.2).sub.2OR', --(CH.sub.2)OR', CH.sub.2CN,
optionally substituted phenyl or phenoxy, --N(R')(R'),
--NR'C(O)OR', --NR'C(O)R', --(CH.sub.2).sub.2N(R')(R'), or
--(CH.sub.2)N(R')(R'); and WR.sup.W5 is selected from hydrogen,
halo, --OH, NH.sub.2, CN, CHF.sub.2, NHR', N(R').sub.2, --NHC(O)R',
--NHC(O)OR', NHSO.sub.2R', --OR', CH.sub.2OH, CH.sub.2N(R').sub.2,
C(O)OR', C(O)N(R').sub.2, SO.sub.2NHR', SO.sub.2N(R').sub.2,
OSO.sub.2N(R').sub.2, OSO.sub.2CF.sub.3, or CH.sub.2NHC(O)OR'.
56. The method according to claim 53 wherein said compound has the
formula VA-2: ##STR00074## wherein: ring B is a 5-7 membered
monocyclic or bicyclic, heterocyclic or heteroaryl ring optionally
substituted with up to n occurrences of -Q-R.sup.Q, Q is W; R.sup.Q
is R.sup.W; m is 0-4; and n is 0-4.
57. The method according to claim 53 wherein said compound has the
formula VA-3: ##STR00075## wherein: Q is W; R.sup.Q is R.sup.W; m
is 0-4; and n is 0-4.
58. The method according to claim 53, wherein said compound has
formula VB-1: ##STR00076## wherein: R.sup.W1 is hydrogen or C1-C6
aliphatic; each of R.sup.W3 is hydrogen or C1-C6 aliphatic; or
optionally both R.sup.W3 taken together form a C3-C6 cycloalkyl or
heterocyclic ring having up to two heteroatoms selected from O, S,
or NR', wherein said ring is optionally substituted with up to two
WR.sup.W substituents; and m is 0-4.
59. The method according to claim 58, wherein WR.sup.W1 is
hydrogen, C1-C6 aliphatic, C(O)C1-C6 aliphatic, or C(O)OC1-C6
aliphatic.
60. The method according to claim 58, wherein each R.sup.W3 is
hydrogen, C1-C4 alkyl; or both R.sup.W3 taken together form a C3-C6
cycloaliphatic ring or 5-7 membered heterocyclic ring having up to
two heteroatoms selected from O, S, or N, wherein said
cycloaliphatic or heterocyclic ring is optionally substituted with
up to three substituents selected from WR.sup.W1.
61. The method according to claim 53, wherein said compound has
formula VB-2: ##STR00077## wherein: ring A.sub.2 is a phenyl or a
5-6 membered heteroaryl ring, wherein ring A.sub.2 and the phenyl
ring fused thereto together have up 4 substituents independently
selected from WR.sup.W; and m is 0-4.
62. The method according to claim 61 wherein ring A.sub.2 is an
optionally substituted 5-membered ring selected from pyrrolyl,
furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl,
thiadiazolyl, oxadiazolyl, or triazolyl.
63. The method according to claim 61, wherein ring A.sub.2 is
selected from: ##STR00078## wherein said ring is optionally
substituted.
64. The method according to claim 63, wherein said compound has
formula VB-3: ##STR00079## wherein: G.sub.4 is hydrogen, halo, CN,
CF.sub.3, CHF.sub.2, CH.sub.2F, optionally substituted C1-C6
aliphatic, aryl-C1-C6 alkyl, or a phenyl, wherein G.sub.4 is
optionally substituted with up to 4 WR.sup.W substituents; wherein
up to two methylene units of said C1-C6 aliphatic or C1-C6 alkyl is
optionally replaced with --CO--, --CONR'--, --CO.sub.2--, --OCO--,
--NR'CO.sub.2--, --O--, --NR'CONR'--, --OCONR'--, --NR'CO--, --S--,
--NR'--, --SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--;
G.sub.5 is hydrogen, CN, or an optionally substituted C1-C6
aliphatic; wherein said indole ring system is further optionally
substituted with up to 3 substituents independently selected from
WR.sup.W.
65. The method according to claim 64, wherein G.sub.4 is hydrogen,
and G.sub.5 is C1-C6 aliphatic, wherein said aliphatic is
optionally substituted with C1-C6 alkyl, halo, cyano, or CF.sub.3,
and wherein up to two methylene units of said C1-C6 aliphatic or
C1-C6 alkyl is optionally replaced with --CO--, --CONR'--,
--CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--, --NR'CONR'--,
--OCONR'--, --NR'CO--, --S--, --NR'--, --SO.sub.2NR'--,
NR'SO.sub.2--, or --NR'SO.sub.2NR'--.
66. The method according to claim 64, wherein G.sub.4 is hydrogen,
and G.sub.5 is cyano, methyl, ethyl, propyl, isopropyl, butyl,
sec-butyl, t-butyl, cyanomethyl, methoxyethyl, CH.sub.2C(O)OMe,
(CH.sub.2).sub.2--NHC(O)O-tert-But, or cyclopentyl.
67. The method according to claim 64, wherein G.sub.5 is hydrogen,
CN or CF.sub.3, and G.sub.4 is halo, C1-C6 aliphatic or phenyl,
wherein said aliphatic or phenyl is optionally substituted with
C1-C6 alkyl, halo, cyano, or CF.sub.3, wherein up to two methylene
units of said C1-C6 aliphatic or C1-C6 alkyl is optionally replaced
with --CO--, --CONR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--,
--O--, --NR'CONR'--, --OCONR'--, --NR'CO--, --S--, --NR'--,
--SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--.
68. The method according to claim 67, wherein G.sub.5 is hydrogen,
CN or CF.sub.3, and G.sub.4 is halo, ethoxycarbonyl, t-butyl,
2-methoxyphenyl, 2-ethoxyphenyl,
(4-C(O)NH(CH.sub.2).sub.2--NMe.sub.2)-phenyl,
2-methoxy-4-chloro-phenyl, pyridine-3-yl, 4-isopropylphenyl,
2,6-dimethoxyphenyl, sec-butylaminocarbonyl, ethyl, t-butyl, or
piperidin-1-ylcarbonyl.
69. The method according to claim 35, wherein said compound is
selected from: ##STR00080## ##STR00081##
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of International
Application No. PCT/US2008/064646 filed May 23, 2008 which in turn
claims the benefit under 35 U.S.C. .sctn.119, to U.S. Provisional
Application No. 60/931,775 filed May 25, 2007 and entitled
"MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE
REGULATOR," and U.S. Provisional Application No. 60/968,704 filed
Aug. 29, 2007 and entitled "MODULATORS OF CYSTIC FIBROSIS
TRANSMEMBRANE CONDUCTANCE REGULATOR," the entire contents of each
of the above applications being incorporated herein by
reference.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to modulators of cystic
fibrosis transmembrane conductance regulator ("CFTR"), compositions
thereof, and methods therewith. The present invention also relates
to methods of treating CFTR mediated diseases using such
modulators.
BACKGROUND OF THE INVENTION
[0003] ABC transporters are a family of membrane transporter
proteins that regulate the transport of a wide variety of
pharmacological agents, potentially toxic drugs, and xenobiotics,
as well as anions. ABC transporters are homologous membrane
proteins that bind and use cellular adenosine triphosphate (ATP)
for their specific activities. Some of these transporters were
discovered as multidrug resistance proteins (like the MDR1-P
glycoprotein, or the multidrug resistance protein, MRP1), defending
malignant cancer cells against chemotherapeutic agents. To date, 48
ABC Transporters have been identified and grouped into 7 families
based on their sequence identity and function.
[0004] ABC transporters regulate a variety of important
physiological roles within the body and provide defense against
harmful environmental compounds. Because of this, they represent
important potential drug targets for the treatment of diseases
associated with defects in the transporter, prevention of drug
transport out of the target cell, and intervention in other
diseases in which modulation of ABC transporter activity may be
beneficial.
[0005] One member of the ABC transporter family commonly associated
with disease is the cAMP/ATP-mediated anion channel, CFTR. CFTR is
expressed in a variety of cells types, including absorptive and
secretory epithelia cells, where it regulates anion flux across the
membrane, as well as the activity of other ion channels and
proteins. In epithelia cells, normal functioning of CFTR is
critical for the maintenance of electrolyte transport throughout
the body, including respiratory and digestive tissue. CFTR is
composed of approximately 1480 amino acids that encode a protein
made up of a tandem repeat of transmembrane domains, each
containing six transmembrane helices and a nucleotide binding
domain. The two transmembrane domains are linked by a large, polar,
regulatory (R)-domain with multiple phosphorylation sites that
regulate channel activity and cellular trafficking.
[0006] The gene encoding CFTR has been identified and sequenced
(See Gregory, R. J. et al. (1990) Nature 347:382-386; Rich, D. P.
et al. (1990) Nature 347:358-362), (Riordan, J. R. et al. (1989)
Science 245:1066-1073). A defect in this gene causes mutations in
CFTR resulting in cystic fibrosis ("CF"), the most common fatal
genetic disease in humans. Cystic fibrosis affects approximately
one in every 2,500 infants in the United States. Within the general
United States population, up to 10 million people carry a single
copy of the defective gene without apparent ill effects. In
contrast, individuals with two copies of the CF associated gene
suffer from the debilitating and fatal effects of CF, including
chronic lung disease.
[0007] In patients with cystic fibrosis, mutations in CFTR
endogenously expressed in respiratory epithelia leads to reduced
apical anion secretion causing an imbalance in ion and fluid
transport. The resulting decrease in anion transport contributes to
enhanced mucus accumulation in the lung and the accompanying
microbial infections that ultimately cause death in CF patients. In
addition to respiratory disease, CF patients typically suffer from
gastrointestinal problems and pancreatic insufficiency that, if
left untreated, results in death. In addition, the majority of
males with cystic fibrosis are infertile and fertility is decreased
among females with cystic fibrosis. In contrast to the severe
effects of two copies of the CF associated gene, individuals with a
single copy of the CF associated gene exhibit increased resistance
to cholera and to dehydration resulting from diarrhea--perhaps
explaining the relatively high frequency of the CF gene within the
population.
[0008] Sequence analysis of the CFTR gene of CF chromosomes has
revealed a variety of disease causing mutations (Cutting, G. R. et
al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell
61:863:870; and Kerem, B-S. et al. (1989) Science 245:1073-1080;
Kerem, B-S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451).
To date, >1000 disease causing mutations in the CF gene have
been identified (http://www.genet.sickkids.on.ca/cftr/). The most
prevalent mutation is a deletion of phenylalanine at position 508
of the CFTR amino acid sequence, and is commonly referred to as
.DELTA.F508-CFTR. This mutation occurs in approximately 70% of the
cases of cystic fibrosis and is associated with a severe
disease.
[0009] The deletion of residue 508 in .DELTA.F508-CFTR prevents the
nascent protein from folding correctly. This results in the
inability of the mutant protein to exit the ER, and traffic to the
plasma membrane. As a result, the number of channels present in the
membrane is far less than observed in cells expressing wild-type
CFTR. In addition to impaired trafficking, the mutation results in
defective channel gating. Together, the reduced number of channels
in the membrane and the defective gating lead to reduced anion
transport across epithelia leading to defective ion and fluid
transport. (Quinton, P. M. (1990), FASEB J. 4: 2709-2727). Studies
have shown, however, that the reduced numbers of .DELTA.F508-CFTR
in the membrane are functional, albeit less than wild-type CFTR.
(Dalemans et al. (1991), Nature Lond. 354: 526-528; Denning et al.,
supra; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50).
In addition to .DELTA.F508-CFTR, other disease causing mutations in
CFTR that result in defective trafficking, synthesis, and/or
channel gating could be up- or down-regulated to alter anion
secretion and modify disease progression and/or severity.
[0010] Although CFTR transports a variety of molecules in addition
to anions, it is clear that this role (the transport of anions)
represents one element in an important mechanism of transporting
ions and water across the epithelium. The other elements include
the epithelial Na.sup.+ channel, ENaC, Na.sup.+/2Cl.sup.-/K.sup.+
co-transporter, Na.sup.+--K.sup.+-ATPase pump and the basolateral
membrane K.sup.+ channels, that are responsible for the uptake of
chloride into the cell.
[0011] These elements work together to achieve directional
transport across the epithelium via their selective expression and
localization within the cell. Chloride absorption takes place by
the coordinated activity of ENaC and CFTR present on the apical
membrane and the Na.sup.+--K.sup.+-ATPase pump and Cl-- channels
expressed on the basolateral surface of the cell. Secondary active
transport of chloride from the luminal side leads to the
accumulation of intracellular chloride, which can then passively
leave the cell via Cl.sup.- channels, resulting in a vectorial
transport. Arrangement of Na.sup.+/2Cl.sup.-/K.sup.+
co-transporter, Na.sup.+--K.sup.+-ATPase pump and the basolateral
membrane K.sup.+ channels on the basolateral surface and CFTR on
the luminal side coordinate the secretion of chloride via CFTR on
the luminal side. Because water is probably never actively
transported itself, its flow across epithelia depends on tiny
transepithelial osmotic gradients generated by the bulk flow of
sodium and chloride.
[0012] In addition to cystic fibrosis, modulation of CFTR activity
may be beneficial for other diseases not directly caused by
mutations in CFTR, such as secretory diseases and other protein
folding diseases mediated by CFTR. These include, but are not
limited to, chronic obstructive pulmonary disease (COPD), dry eye
disease, and Sjogren's Syndrome. COPD is characterized by airflow
limitation that is progressive and not fully reversible. The
airflow limitation is due to mucus hypersecretion, emphysema, and
bronchiolitis. Activators of mutant or wild-type CFTR offer a
potential treatment of mucus hypersecretion and impaired
mucociliary clearance that is common in COPD. Specifically,
increasing anion secretion across CFTR may facilitate fluid
transport into the airway surface liquid to hydrate the mucus and
optimized periciliary fluid viscosity. This would lead to enhanced
mucociliary clearance and a reduction in the symptoms associated
with COPD. Dry eye disease is characterized by a decrease in tear
aqueous production and abnormal tear film lipid, protein and mucin
profiles. There are many causes of dry eye, some of which include
age, Lasik eye surgery, arthritis, medications, chemical/thermal
burns, allergies, and diseases, such as cystic fibrosis and
Sjogrens's syndrome. Increasing anion secretion via CFTR would
enhance fluid transport from the corneal endothelial cells and
secretory glands surrounding the eye to increase corneal hydration.
This would help to alleviate the symptoms associated with dry eye
disease. Sjogrens's syndrome is an autoimmune disease in which the
immune system attacks moisture-producing glands throughout the
body, including the eye, mouth, skin, respiratory tissue, liver,
vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as
well as lung disease. The disease is also associated with
rheumatoid arthritis, systemic lupus, systemic sclerosis, and
polymypositis/dermatomyositis. Defective protein trafficking is
believed to cause the disease, for which treatment options are
limited. Modulators of CFTR activity may hydrate the various organs
afflicted by the disease and help to elevate the associated
symptoms.
[0013] As discussed above, it is believed that the deletion of
residue 508 in .DELTA.F508-CFTR prevents the nascent protein from
folding correctly, resulting in the inability of this mutant
protein to exit the ER, and traffic to the plasma membrane. As a
result, insufficient amounts of the mature protein are present at
the plasma membrane and chloride transport within epithelial
tissues is significantly reduced. In fact, this cellular phenomenon
of defective ER processing of ABC transporters by the ER machinery,
has been shown to be the underlying basis not only for CF disease,
but for a wide range of other isolated and inherited diseases. The
two ways that the ER machinery can malfunction is either by loss of
coupling to ER export of the proteins leading to degradation, or by
the ER accumulation of these defective/misfolded proteins [Aridor
M, et al., Nature Med., 5(7), pp 745-751 (1999); Shastry, B. S., et
al., Neurochem. International, 43, pp 1-7 (2003); Rutishauser, J.,
et al., Swiss Med Wkly, 132, pp 211-222 (2002); Morello, J P et
al., TIPS, 21, pp. 466-469 (2000); Bross P., et al., Human Mut.,
14, pp. 186-198 (1999)]. The diseases associated with the first
class of ER malfunction are cystic fibrosis (due to misfolded
.DELTA.F508-CFTR as discussed above), hereditary emphysema (due to
al-antitrypsin; non Piz variants), hereditary hemochromatosis,
hoagulation-fibrinolysis deficiencies, such as protein C
deficiency, Type 1 hereditary angioedema, lipid processing
deficiencies, such as familial hypercholesterolemia, Type 1
chylomicronemia, abetalipoproteinemia, lysosomal storage diseases,
such as I-cell disease/pseudo-Hurler, Mucopolysaccharidoses (due to
lysosomal processing enzymes), Sandhof/Tay-Sachs (due to
.beta.-hexosaminidase), Crigler-Najjar type II (due to
UDP-glucuronyl-sialyc-transferase),
polyendocrinopathy/hyperinsulemia, Diabetes mellitus (due to
insulin receptor), Laron dwarfism (due to growth hormone receptor),
myleoperoxidase deficiency, primary hypoparathyroidism (due to
preproparathyroid hormone), melanoma (due to tyrosinase). The
diseases associated with the latter class of ER malfunction are
Glycanosis CDG type 1, hereditary emphysema (due to
.alpha.1-Antitrypsin (PiZ variant), congenital hyperthyroidism,
osteogenesis imperfecta (due to Type I, II, IV procollagen),
hereditary hypofibrinogenemia (due to fibrinogen), ACT deficiency
(due to .alpha.1-antichymotrypsin), Diabetes insipidus (DI),
neurophyseal DI (due to vasopvessin hormone/V2-receptor),
neprogenic DI (due to aquaporin II), Charcot-Marie Tooth syndrome
(due to peripheral myelin protein 22), Perlizaeus-Merzbacher
disease, neurodegenerative diseases such as Alzheimer's disease
(due to .beta.APP and presenilins), Parkinson's disease,
amyotrophic lateral sclerosis, progressive supranuclear plasy,
Pick's disease, several polyglutamine neurological disorders asuch
as Huntington, spinocerebullar ataxia type I, spinal and bulbar
muscular atrophy, dentatorubal pallidoluysian, and myotonic
dystrophy, as well as spongiform encephalopathies, such as
hereditary Creutzfeldt-Jakob disease (due to prion protein
processing defect), Fabry disease (due to lysosomal
.alpha.-galactosidase A) and Straussler-Scheinker syndrome (due to
Prp processing defect).
[0014] In addition to up-regulation of CFTR activity, reducing
anion secretion by CFTR modulators may be beneficial for the
treatment of secretory diarrheas, in which epithelial water
transport is dramatically increased as a result of secretagogue
activated chloride transport. The mechanism involves elevation of
cAMP and stimulation of CFTR.
[0015] Although there are numerous causes of diarrhea, the major
consequences of diarrheal diseases, resulting from excessive
chloride transport are common to all, and include dehydration,
acidosis, impaired growth and death.
[0016] Acute and chronic diarrheas represent a major medical
problem in many areas of the world. Diarrhea is both a significant
factor in malnutrition and the leading cause of death (5,000,000
deaths/year) in children less than five years old.
[0017] Secretory diarrheas are also a dangerous condition in
patients of acquired immunodeficiency syndrome (AIDS) and chronic
inflammatory bowel disease (IBD). 16 million travelers to
developing countries from industrialized nations every year develop
diarrhea, with the severity and number of cases of diarrhea varying
depending on the country and area of travel.
[0018] Diarrhea in barn animals and pets such as cows, pigs and
horses, sheep, goats, cats and dogs, also known as scours, is a
major cause of death in these animals. Diarrhea can result from any
major transition, such as weaning or physical movement, as well as
in response to a variety of bacterial or viral infections and
generally occurs within the first few hours of the animal's
life.
[0019] The most common diarrheal causing bacteria is
enterotoxogenic E. coli (ETEC) having the K99 pilus antigen. Common
viral causes of diarrhea include rotavirus and coronavirus. Other
infectious agents include cryptosporidium, giardia lamblia, and
salmonella, among others.
[0020] Symptoms of rotaviral infection include excretion of watery
feces, dehydration and weakness. Coronavirus causes a more severe
illness in the newborn animals, and has a higher mortality rate
than rotaviral infection. Often, however, a young animal may be
infected with more than one virus or with a combination of viral
and bacterial microorganisms at one time. This dramatically
increases the severity of the disease.
[0021] Accordingly, there is a need for modulators of CFTR
activity, and compositions thereof, that can be used to modulate
the activity of the CFTR in the cell membrane of a mammal.
[0022] There is a need for methods of treating CFTR mediated
diseases using such modulators of CFTR activity.
[0023] There is a need for methods of modulating CFTR activity in
an ex vivo cell membrane of a mammal.
SUMMARY OF THE INVENTION
[0024] It has now been found that compounds of this invention, and
pharmaceutically acceptable compositions thereof, are useful as
modulators of ABC transporter activity. These compounds have the
general formula I or formula I':
##STR00001##
[0025] or a pharmaceutically acceptable salt thereof, wherein
R.sup.1, R.sup.2, R.sup.3, R.sup.4, and Ar.sup.1 are described
generally and in classes and subclasses below.
[0026] These compounds and pharmaceutically acceptable compositions
are useful for treating or lessening the severity of a variety of
diseases, disorders, or conditions, including, but not limited to,
cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis,
Coagulation-Fibrinolysis deficiencies, such as Protein C
deficiency, Type 1 hereditary angioedema, Lipid processing
deficiencies, such as Familial hypercholesterolemia, Type 1
chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases,
such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses,
Sandhof/Tay-Sachs, Crigler-Najjar type II,
Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron
dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism,
Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital
hyperthyroidism, Osteogenesis imperfecta, Hereditary
hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI),
Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome,
Perlizaeus-Merzbacher disease, neurodegenerative diseases such as
Alzheimer's disease, Parkinson's disease, Amyotrophic lateral
sclerosis, Progressive supranuclear plasy, Pick's disease, several
polyglutamine neurological disorders asuch as Huntington,
Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy,
Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as
Spongiform encephalopathies, such as Hereditary Creutzfeldt-Jakob
disease, Fabry disease, Straussler-Scheinker syndrome, COPD,
dry-eye disease, and Sjogren's disease.
DETAILED DESCRIPTION OF THE INVENTION
I. General Description of Compounds of the Invention
[0027] The present invention relates to compounds of formula I or
formula I' useful as modulators of ABC transporter activity:
##STR00002##
[0028] or a pharmaceutically acceptable salt thereof, wherein:
[0029] Ar.sup.1 is a 5-6 membered aromatic monocyclic ring having
0-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein said ring is optionally fused to a 5-12 membered
monocyclic or bicyclic, aromatic, partially unsaturated, or
saturated ring, wherein each ring contains 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, wherein
Ar.sup.1 has m substituents, each independently selected from
--WR.sup.W;
[0030] W is a bond or is an optionally substituted C.sub.1-C.sub.6
alkylidene chain wherein up to two methylene units of W are
optionally and independently replaced by --CO--, --CS--, --COCO--,
--CONR'--, --CONR'NR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--,
--O--, --NR'CONR'--, --OCONR'--, --NR'NR', --NR'NR'CO--, --NR'CO--,
--S--, --SO, --SO.sub.2--, --NR'--, --SO.sub.2NR'--, NR'SO.sub.2--,
or --NR'SO.sub.2NR'--;
[0031] R.sup.W is independently R', halo, cyano, CF.sub.3,
CHF.sub.2, OCHF.sub.2, Me, Et, CH(Me).sub.2, CHMeEt, n-propyl,
t-butyl, OH, OMe, OEt, OPh, O-fluorophenyl, O-difluorophenyl,
O-methoxyphenyl, O-tolyl, O-benzyl, SMe, SCF.sub.3, SCHF.sub.2,
SEt, CH.sub.2CN, NH.sub.2, NHMe, N(Me).sub.2, NHEt, N(Et).sub.2,
C(O)CH.sub.3, C(O)Ph, C(O)NH.sub.2, SPh, SO.sub.2-(amino-pyridyl),
SO.sub.2NH.sub.2, SO.sub.2Ph, SO.sub.2NHPh, SO.sub.2--N-morpholino,
SO.sub.2--N-pyrrolidyl, N-pyrrolyl, N-morpholino, 1-piperidyl,
phenyl, benzyl, (cyclohexyl-methylamino)methyl,
4-Methyl-2,4-dihydro-pyrazol-3-one-2-yl, benzimidazol-2yl,
furan-2-yl, 4-methyl-4H-[1,2,4]triazol-3-yl,
3-(4'-chlorophenyl)-[1,2,4]oxadiazol-5-yl, NHC(O)Me, NHC(O)Et,
NHC(O)Ph, NHSO.sub.2Me, 2-indolyl, 5-indolyl, --CH.sub.2CH.sub.2OH,
--OCF.sub.3, O-(2,3-dimethylphenyl), 5-methylfuryl,
--SO.sub.2--N-piperidyl, 2-tolyl, 3-tolyl, 4-tolyl, O-butyl,
NHCO.sub.2C(Me).sub.3, CO.sub.2C(Me).sub.3, isopropenyl, n-butyl,
O-(2,4-dichlorophenyl), NHSO.sub.2PhMe,
O-(3-chloro-5-trifluoromethyl-2-pyridyl), phenylhydroxymethyl,
2,5-dimethylpyrrolyl, NHCOCH.sub.2C(Me).sub.3,
O-(2-tert-butyl)phenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl,
4-hydroxymethyl phenyl, 4-dimethylaminophenyl,
2-trifluoromethylphenyl, 3-trifluoromethylphenyl,
4-trifluoromethylphenyl, 4-cyanomethylphenyl, 4-isobutylphenyl,
3-pyridyl, 4-pyridyl, 4-isopropylphenyl, 3-isopropylphenyl,
2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl,
3,4-methylenedioxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl,
4-ethoxyphenyl, 2-methylthiophenyl, 4-methylthiophenyl,
2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl,
3,4-dimethoxyphenyl, 5-chloro-2-methoxyphenyl, 2-OCF.sub.3-phenyl,
3-trifluoromethoxy-phenyl, 4-trifluoromethoxyphenyl,
2-phenoxyphenyl, 4-phenoxyphenyl, 2-fluoro-3-methoxy-phenyl,
2,4-dimethoxy-5-pyrimidyl, 5-isopropyl-2-methoxyphenyl,
2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-cyanophenyl,
3-chlorophenyl, 4-chlorophenyl, 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl,
3,5-difluorophenyl, 3-chloro-4-fluoro-phenyl, 3,5-dichlorophenyl,
2,5-dichlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl,
2,4-dichlorophenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonyl
phenyl, 3-isopropyloxycarbonylphenyl, 3-acetamidophenyl,
4-fluoro-3-methylphenyl, 4-methanesulfinyl-phenyl,
4-methanesulfonyl-phenyl,
4-N-(2-N,N-dimethylaminoethyl)carbamoylphenyl, 5-acetyl-2-thienyl,
2-benzothienyl, 3-benzothienyl, furan-3-yl, 4-methyl-2-thienyl,
5-cyano-2-thienyl, N'-phenylcarbonyl-N-piperazinyl, --NHCO.sub.2Et,
--NHCO.sub.2Me, N-pyrrolidinyl,
--NHSO.sub.2(CH.sub.2).sub.2N-piperidine,
--NHSO.sub.2(CH.sub.2).sub.2N-morpholine,
--NHSO.sub.2(CH.sub.2).sub.2N(Me).sub.2,
COCH.sub.2N(Me)COCH.sub.2NHMe, --CO.sub.2Et, O-propyl,
--CH.sub.2CH.sub.2NHCO.sub.2C(Me).sub.3, aminomethyl, pentyl,
adamantyl, cyclopentyl, ethoxyethyl, C(Me).sub.2CH.sub.2OH,
C(Me).sub.2CO.sub.2Et, --CHOHMe, CH.sub.2CO.sub.2Et,
--CMe.sub.2CH.sub.2NHCO.sub.2C(Me).sub.3, O(CH.sub.2).sub.2OEt,
O(CH.sub.2).sub.2OH, CO.sub.2Me, hydroxymethyl,
1-methyl-1-cyclohexyl, 1-methyl-1-cyclooctyl,
1-methyl-1-cycloheptyl, C(Et).sub.2C(Me).sub.3, C(Et).sub.3,
CONHCH.sub.2CH(Me).sub.2, 2-aminomethyl-phenyl, ethenyl,
1-piperidinylcarbonyl, ethynyl, cyclohexyl, 4-methylpiperidinyl,
--OCO.sub.2Me, --C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2CH(Me).sub.2,
--C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2CH.sub.2CH.sub.3,
--C(Me).sub.2CH.sub.2NHCO.sub.2Et,
--C(Me).sub.2CH.sub.2NHCO.sub.2Me,
--C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2C(Me).sub.3,
--CH.sub.2NHCOCF.sub.3, --CH.sub.2NHCO.sub.2C(Me).sub.3,
--C(Me).sub.2CH.sub.2NHCO.sub.2(CH.sub.2).sub.3CH.sub.3,
C(Me).sub.2CH.sub.2NHCO.sub.2(CH.sub.2).sub.2OMe,
C(OH)(CF.sub.3).sub.2,
--C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2-tetrahydrofurane-3-yl,
C(Me).sub.2CH.sub.2O(CH.sub.2).sub.2OMe, or
3-ethyl-2,6-dioxopiperidin-3-yl;
[0032] m is 0-5;
[0033] k is 0-2;
[0034] each of R.sup.1 is independently --X--R.sup.X;
[0035] X is a bond or is an optionally substituted C.sub.1-C.sub.6
alkylidene chain wherein up to two methylene units of X are
optionally and independently replaced by --CO--, --CS--, --COCO--,
--CONR'--, --CONR'NR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--,
--O--, --NR'CONR'--, --OCONR'--, --NR'NR', --NR'NR'CO--, --NR'CO--,
--S--, --SO, --SO.sub.2--, --NR'--, --SO.sub.2NR'--, NR'SO.sub.2--,
or --NR'SO.sub.2NR'--;
[0036] R.sup.X is independently R', halo, NO.sub.2, CN, CF.sub.3,
or OCF.sub.3;
[0037] R.sup.2 is hydrogen;
[0038] R.sup.3 is hydrogen;
[0039] R.sup.4 is hydrogen or a C.sub.1-6 aliphatic group
optionally substituted with --X--R.sup.X;
[0040] R' is independently selected from hydrogen or an optionally
substituted group selected from a C.sub.1-C.sub.8 aliphatic group,
a 3-8-membered saturated, partially unsaturated, or fully
unsaturated monocyclic ring having 0-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or an 8-12 membered
saturated, partially unsaturated, or fully unsaturated bicyclic
ring system having 0-5 heteroatoms independently selected from
nitrogen, oxygen, or sulfur; or two occurrences of R' are taken
together with the atom(s) to which they are bound to form an
optionally substituted 3-12 membered saturated, partially
unsaturated, or fully unsaturated monocyclic or bicyclic ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur.
2. Compounds and Definitions
[0041] Compounds of this invention include those described
generally above, and are further illustrated by the classes,
subclasses, and species disclosed herein. As used herein, the
following definitions shall apply unless otherwise indicated.
[0042] The term "ABC-transporter" as used herein means an
ABC-transporter protein or a fragment thereof comprising at least
one binding domain, wherein said protein or fragment thereof is
present in vivo or in vitro. The term "binding domain" as used
herein means a domain on the ABC-transporter that can bind to a
modulator. See, e.g., Hwang, T. C. et al., J. Gen. Physiol. (1998):
111(3), 477-90.
[0043] The term "CFTR" as used herein means cystic fibrosis
transmembrane conductance regulator or a mutation thereof capable
of regulator activity, including, but not limited to, .DELTA.F508
CFTR and G551D CFTR (see, e.g.,
http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
[0044] The term "modulating" as used herein means increasing or
decreasing by a measurable amount.
[0045] For purposes of this invention, the chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, Handbook of Chemistry and Physics, 75.sup.th Ed.
Additionally, general principles of organic chemistry are described
in "Organic Chemistry", Thomas Sorrell, University Science Books,
Sausalito: 1999, and "March's Advanced Organic Chemistry", 5.sup.th
Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New
York: 2001, the entire contents of which are hereby incorporated by
reference.
[0046] As described herein, compounds of the invention may
optionally be substituted with one or more substituents, such as
are illustrated generally above, or as exemplified by particular
classes, subclasses, and species of the invention. It will be
appreciated that the phrase "optionally substituted" is used
interchangeably with the phrase "substituted or unsubstituted." In
general, the term "substituted", whether preceded by the term
"optionally" or not, refers to the replacement of hydrogen radicals
in a given structure with the radical of a specified substituent.
Unless otherwise indicated, an optionally substituted group may
have a substituent at each substitutable position of the group, and
when more than one position in any given structure may be
substituted with more than one substituent selected from a
specified group, the substituent may be either the same or
different at every position. Combinations of substituents
envisioned by this invention are preferably those that result in
the formation of stable or chemically feasible compounds. The term
"stable", as used herein, refers to compounds that are not
substantially altered when subjected to conditions to allow for
their production, detection, and preferably their recovery,
purification, and use for one or more of the purposes disclosed
herein. In some embodiments, a stable compound or chemically
feasible compound is one that is not substantially altered when
kept at a temperature of 40.degree. C. or less, in the absence of
moisture or other chemically reactive conditions, for at least a
week.
[0047] The term "aliphatic" or "aliphatic group", as used herein,
means a straight-chain (i.e., unbranched) or branched, substituted
or unsubstituted hydrocarbon chain that is completely saturated or
that contains one or more units of unsaturation, or a monocyclic
hydrocarbon or bicyclic hydrocarbon that is completely saturated or
that contains one or more units of unsaturation, but which is not
aromatic (also referred to herein as "carbocycle" "cycloaliphatic"
or "cycloalkyl"), that has a single point of attachment to the rest
of the molecule. Unless otherwise specified, aliphatic groups
contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic
groups contain 1-10 aliphatic carbon atoms. In other embodiments,
aliphatic groups contain 1-8 aliphatic carbon atoms. In still other
embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms,
and in yet other embodiments aliphatic groups contain 1-4 aliphatic
carbon atoms. In some embodiments, "cycloaliphatic" (or
"carbocycle" or "cycloalkyl") refers to a monocyclic
C.sub.3-C.sub.8 hydrocarbon or bicyclic or tricyclic
C.sub.8-C.sub.14 hydrocarbon that is completely saturated or that
contains one or more units of unsaturation, but which is not
aromatic, that has a single point of attachment to the rest of the
molecule wherein any individual ring in said bicyclic ring system
has 3-7 members. Suitable aliphatic groups include, but are not
limited to, linear or branched, substituted or unsubstituted alkyl,
alkenyl, alkynyl groups and hybrids thereof such as
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
Suitable cycloaliphatic groups include cycloalkyl, bicyclic
cycloalkyl (e.g., decalin), bridged bicycloalkyl such as norbornyl
or [2.2.2]bicyclo-octyl, or bridged tricyclic such as
adamantyl.
[0048] The term "heteroaliphatic", as used herein, means aliphatic
groups wherein one or two carbon atoms are independently replaced
by one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon.
Heteroaliphatic groups may be substituted or unsubstituted,
branched or unbranched, cyclic or acyclic, and include
"heterocycle", "heterocyclyl", "heterocycloaliphatic", or
"heterocyclic" groups.
[0049] The term "heterocycle", "heterocyclyl",
"heterocycloaliphatic", or "heterocyclic" as used herein means
non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in
which one or more ring members is an independently selected
heteroatom. In some embodiments, the "heterocycle", "heterocyclyl",
"heterocycloaliphatic", or "heterocyclic" group has three to
fourteen ring members in which one or more ring members is a
heteroatom independently selected from oxygen, sulfur, nitrogen, or
phosphorus, and each ring in the system contains 3 to 7 ring
members.
[0050] The term "heteroatom" means one or more of oxygen, sulfur,
nitrogen, phosphorus, or silicon (including, any oxidized form of
nitrogen, sulfur, phosphorus, or silicon; the quaternized form of
any basic nitrogen or; a substitutable nitrogen of a heterocyclic
ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl) or NR.sup.+ (as in N-substituted pyrrolidinyl)).
[0051] The term "unsaturated", as used herein, means that a moiety
has one or more units of unsaturation.
[0052] The term "alkoxy", or "thioalkyl", as used herein, refers to
an alkyl group, as previously defined, attached to the principal
carbon chain through an oxygen ("alkoxy") or sulfur ("thioalkyl")
atom.
[0053] The terms "haloaliphatic" and "haloalkoxy" means aliphatic
or alkoxy, as the case may be, substituted with one or more halo
atoms. The term "halogen" or "halo" means F, Cl, Br, or I. Examples
of haloaliphatic include --CHF.sub.2, --CH.sub.2F, --CF.sub.3,
--CF.sub.2--, or perhaloalkyl, such as, --CF.sub.2CF.sub.3.
[0054] The term "aryl" used alone or as part of a larger moiety as
in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic,
bicyclic, and tricyclic ring systems having a total of five to
fourteen ring members, wherein at least one ring in the system is
aromatic and wherein each ring in the system contains 3 to 7 ring
members. The term "aryl" may be used interchangeably with the term
"aryl ring". The term "aryl" also refers to heteroaryl ring systems
as defined hereinbelow.
[0055] The term "heteroaryl", used alone or as part of a larger
moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to
monocyclic, bicyclic, and tricyclic ring systems having a total of
five to fourteen ring members, wherein at least one ring in the
system is aromatic, at least one ring in the system contains one or
more heteroatoms, and wherein each ring in the system contains 3 to
7 ring members. The term "heteroaryl" may be used interchangeably
with the term "heteroaryl ring" or the term "heteroaromatic".
[0056] An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the
like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy
and the like) group may contain one or more substituents. Suitable
substituents on the unsaturated carbon atom of an aryl or
heteroaryl group are selected from halo; --R.sup.o; --OR.sup.o;
--SR.sup.o; 1,2-methylene-dioxy; 1,2-ethylenedioxy; phenyl (Ph)
optionally substituted with R.sup.o; --O(Ph) optionally substituted
with R.sup.o; --(CH.sub.2).sub.1-.sub.2(Ph), optionally substituted
with R.sup.o; --CH.dbd.CH(Ph), optionally substituted with R.sup.o;
--NO.sub.2; --CN; --N(R.sup.o).sub.2; --NR.sup.oC(O)R.sup.o;
--NR.sup.oC(O)N(R.sup.o).sub.2; --NR.sup.oCO.sub.2R.sup.o;
--NR.sup.oNR.sup.oC(O)R.sup.o;
--NR.sup.oNR.sup.oC(O)N(R.sup.o).sub.2;
--NR.sup.oNR.sup.oCO.sub.2R.sup.o; --C(O)C(O)R.sup.o;
--C(O)CH.sub.2C(O)R.sup.o; --CO.sub.2R.sup.o; --C(O)R.sup.o;
--C(O)N(R.sup.o).sub.2; --OC(O)N(R.sup.o).sub.2;
--S(O).sub.2R.sup.o; --SO.sub.2N(R.sup.o).sub.2; --S(O)R.sup.o;
--NR.sup.oSO.sub.2N(R.sup.o).sub.2; --NR.sup.oSO.sub.2R.sup.o;
--C(.dbd.S)N(R.sup.o).sub.2; --C(.dbd.NH)--N(R.sup.o).sub.2; or
--(CH.sub.2).sub.0-2NHC(O)R.sup.o wherein each independent
occurrence of R.sup.o is selected from hydrogen, optionally
substituted C.sub.1-6 aliphatic, an unsubstituted 5-6 membered
heteroaryl or heterocyclic ring, phenyl, --O(Ph), or
--CH.sub.2(Ph), or, notwithstanding the definition above, two
independent occurrences of R.sup.o, on the same substituent or
different substituents, taken together with the atom(s) to which
each R.sup.o group is bound, form a 3-8-membered cycloalkyl,
heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. Optional
substituents on the aliphatic group of R.sup.o are selected from
NH.sub.2, NH(C.sub.1-4aliphatic), N(C.sub.1-4aliphatic).sub.2,
halo, C.sub.1-4aliphatic, OH, O(C.sub.1-4aliphatic), NO.sub.2, CN,
CO.sub.2H, CO.sub.2(C.sub.1-4aliphatic), O(haloC.sub.1-4aliphatic),
or haloC.sub.1-4aliphatic, wherein each of the foregoing
C.sub.1-4aliphatic groups of R.sup.o is unsubstituted.
[0057] An aliphatic or heteroaliphatic group, or a non-aromatic
heterocyclic ring may contain one or more substituents. Suitable
substituents on the saturated carbon of an aliphatic or
heteroaliphatic group, or of a non-aromatic heterocyclic ring are
selected from those listed above for the unsaturated carbon of an
aryl or heteroaryl group and additionally include the following:
.dbd.O, .dbd.S, .dbd.NNHR*, .dbd.NN(R*).sub.2, .dbd.NNHC(O)R*,
.dbd.NNHCO.sub.2(alkyl), .dbd.NNHSO.sub.2(alkyl), or .dbd.NR*,
where each R* is independently selected from hydrogen or an
optionally substituted C.sub.1-6 aliphatic. Optional substituents
on the aliphatic group of R* are selected from NH.sub.2,
NH(C.sub.1-4aliphatic), N(C.sub.1-4aliphatic).sub.2, halo,
C.sub.1-4 aliphatic, OH, O(C.sub.1-4aliphatic), NO.sub.2, CN,
CO.sub.2H, CO.sub.2(C.sub.1-4 aliphatic), O(halo C.sub.1-4
aliphatic), or halo(C.sub.1-4 aliphatic), wherein each of the
foregoing C.sub.1-4aliphatic groups of R* is unsubstituted.
[0058] Optional substituents on the nitrogen of a non-aromatic
heterocyclic ring are selected from --R.sup.+, --N(R.sup.+).sub.2,
--C(O)R.sup.+, --CO.sub.2R.sup.+, --C(O)C(O)R.sup.+,
--C(O)CH.sub.2C(O)R.sup.+, --SO.sub.2R.sup.+,
--SO.sub.2N(R.sup.+).sub.2, --C(.dbd.S)N(R.sup.+).sub.2,
--C(.dbd.NH)--N(R.sup.+).sub.2, or --NR.sup.+SO.sub.2R.sup.+;
wherein R.sup.+ is hydrogen, an optionally substituted C.sub.1-6
aliphatic, optionally substituted phenyl, optionally substituted
--O(Ph), optionally substituted --CH.sub.2(Ph), optionally
substituted --(CH.sub.2).sub.1-2(Ph); optionally substituted
--CH.dbd.CH(Ph); or an unsubstituted 5-6 membered heteroaryl or
heterocyclic ring having one to four heteroatoms independently
selected from oxygen, nitrogen, or sulfur, or, notwithstanding the
definition above, two independent occurrences of R.sup.+, on the
same substituent or different substituents, taken together with the
atom(s) to which each R.sup.+ group is bound, form a 3-8-membered
cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. Optional substituents on the aliphatic group or the phenyl
ring of R.sup.+ are selected from NH.sub.2, NH(C.sub.1-4
aliphatic), N(C.sub.1-4 aliphatic).sub.2, halo, C.sub.1-4
aliphatic, OH, O(C.sub.1-4 aliphatic), NO.sub.2, CN, CO.sub.2H,
CO.sub.2(C.sub.1-4 aliphatic), O(halo C.sub.1-4 aliphatic), or
halo(C.sub.1-4 aliphatic), wherein each of the foregoing
C.sub.1-4aliphatic groups of R.sup.+ is unsubstituted.
[0059] The term "alkylidene chain" refers to a straight or branched
carbon chain that may be fully saturated or have one or more units
of unsaturation and has two points of attachment to the rest of the
molecule. The term "spirocycloalkylidene" refers to a carbocyclic
ring that may be fully saturated or have one or more units of
unsaturation and has two points of attachment from the same ring
carbon atom to the rest of the molecule.
[0060] As detailed above, in some embodiments, two independent
occurrences of R.sup.o (or R.sup.+, or any other variable similarly
defined herein), are taken together with the atom(s) to which each
variable is bound to form a 3-8-membered cycloalkyl, heterocyclyl,
aryl, or heteroaryl ring having 0-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. Exemplary rings that are
formed when two independent occurrences of R.sup.o (or R.sup.+, or
any other variable similarly defined herein) are taken together
with the atom(s) to which each variable is bound include, but are
not limited to the following: a) two independent occurrences of
R.sup.o (or R.sup.+, or any other variable similarly defined
herein) that are bound to the same atom and are taken together with
that atom to form a ring, for example, N(R.sup.o).sub.2, where both
occurrences of R.sup.o are taken together with the nitrogen atom to
form a piperidin-1-yl, piperazin-1-yl, or morpholin-4-yl group; and
b) two independent occurrences of R.sup.o (or R.sup.+, or any other
variable similarly defined herein) that are bound to different
atoms and are taken together with both of those atoms to form a
ring, for example where a phenyl group is substituted with two
occurrences of OR.sup.o
##STR00003##
these two occurrences of R.sup.o are taken together with the oxygen
atoms to which they are bound to form a fused 6-membered oxygen
containing ring:
##STR00004##
It will be appreciated that a variety of other rings can be formed
when two independent occurrences of R.sup.o (or R.sup.+, or any
other variable similarly defined herein) are taken together with
the atom(s) to which each variable is bound and that the examples
detailed above are not intended to be limiting.
[0061] A substituent bond in, e.g., a bicyclic ring system, as
shown below, means that the substituent can be attached to any
substitutable ring atom on either ring of the bicyclic ring
system:
##STR00005##
[0062] Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereomeric,
and geometric (or conformational)) forms of the structure; for
example, the R and S configurations for each asymmetric center, (Z)
and (E) double bond isomers, and (Z) and (E) conformational
isomers. Therefore, single stereochemical isomers as well as
enantiomeric, diastereomeric, and geometric (or conformational)
mixtures of the present compounds are within the scope of the
invention. Unless otherwise stated, all tautomeric forms of the
compounds of the invention are within the scope of the invention.
E.g., when R.sup.5 in compounds of formula I or formula I' is
hydrogen, compounds of formula I or formula I' may exist as
tautomers:
##STR00006##
[0063] Additionally, unless otherwise stated, structures depicted
herein are also meant to include compounds that differ only in the
presence of one or more isotopically enriched atoms. For example,
compounds having the present structures except for the replacement
of hydrogen by deuterium or tritium, or the replacement of a carbon
by a .sup.13C- or .sup.14C-enriched carbon are within the scope of
this invention. Such compounds are useful, for example, as
analytical tools or probes in biological assays.
3. Description of Exemplary Compounds
[0064] In some embodiments of the present invention, Ar.sup.1 is
selected from:
##STR00007##
[0065] wherein ring A.sub.1 is a 5-6 membered aromatic monocyclic
ring having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; or
[0066] A.sub.1 and A.sub.2, together, is an 8-14 membered aromatic,
bicyclic or tricyclic aryl ring, wherein each ring contains 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
[0067] In some embodiments, A.sub.1 is an optionally substituted 6
membered aromatic ring having 0-4 heteroatoms, wherein said
heteroatom is nitrogen. In some embodiments, A.sub.1 is an
optionally substituted phenyl. Or, A.sub.1 is an optionally
substituted pyridyl, pyrimidinyl, pyrazinyl or triazinyl. Or,
A.sub.1 is an optionally substituted pyrazinyl or triazinyl. Or,
A.sub.1 is an optionally substituted pyridyl.
[0068] In some embodiments, A.sub.1 is an optionally substituted
5-membered aromatic ring having 0-3 heteroatoms, wherein said
heteroatom is nitrogen, oxygen, or sulfur. In some embodiments,
A.sub.1 is an optionally substituted 5-membered aromatic ring
having 1-2 nitrogen atoms. In one embodiment, A.sub.1 is an
optionally substituted 5-membered aromatic ring other than
thiazolyl.
[0069] In some embodiments, A.sub.2 is an optionally substituted 6
membered aromatic ring having 0-4 heteroatoms, wherein said
heteroatom is nitrogen. In some embodiments, A.sub.2 is an
optionally substituted phenyl. Or, A.sub.2 is an optionally
substituted pyridyl, pyrimidinyl, pyrazinyl, or triazinyl.
[0070] In some embodiments, A.sub.2 is an optionally substituted
5-membered aromatic ring having 0-3 heteroatoms, wherein said
heteroatom is nitrogen, oxygen, or sulfur. In some embodiments,
A.sub.2 is an optionally substituted 5-membered aromatic ring
having 1-2 nitrogen atoms. In certain embodiments, A.sub.2 is an
optionally substituted pyrrolyl.
[0071] In some embodiments, A.sub.2 is an optionally substituted
5-7 membered saturated or unsaturated heterocyclic ring having 1-3
heteroatoms independently selected from nitrogen, sulfur, or
oxygen. Exemplary such rings include piperidyl, piperazyl,
morpholinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl,
etc.
[0072] In some embodiments, A.sub.2 is an optionally substituted
5-10 membered saturated or unsaturated carbocyclic ring. In one
embodiment, A.sub.2 is an optionally substituted 5-10 membered
saturated carbocyclic ring. Exemplary such rings include
cyclohexyl, cyclopentyl, etc.
[0073] In some embodiments, ring A.sub.2 is selected from:
##STR00008## ##STR00009## ##STR00010##
wherein ring A.sub.2 is fused to ring A.sub.1 through two adjacent
ring atoms.
[0074] In other embodiments, W is a bond or is an optionally
substituted C.sub.1-C.sub.6 alkylidene chain wherein up to two
methylene units of W are optionally and independently replaced by
O, --CO--, --CS--, --COCO--, --CONR'--, --CONR'NR'--, --CO.sub.2--,
--OCO--, --NR'CO.sub.2--, --O--, --NR'CONR'--, --C(O)NR'--,
--OCONR'--, --NR'NR', --NR'NR'CO--, --NR'CO--, --S--, --SO,
--SO.sub.2--, --NR'--, --SO.sub.2NR'--, NR'SO.sub.2--, or
--NR'SO.sub.2NR'--, and R.sup.W is R' or halo
[0075] In still other embodiments, each occurrence of WR.sup.W is
independently --C1-C3 alkyl, t-butyl, C1-C3 perhaloalkyl, --OH,
--O(C1-C3alkyl), --CF.sub.3, --OCF.sub.3, --SCF.sub.3, --F, --Cl,
--Br, or --COOR', --COR', --O(CH.sub.2).sub.2N(R')(R'),
--O(CH.sub.2)N(R')(R'), --CON(R')(R'), --(CH.sub.2).sub.2OR',
--(CH.sub.2)OR', optionally substituted 5-7 membered heterocylic
ring, optionally substituted 5-7 membered cycloaliphatic group,
optionally substituted monocyclic or bicyclic aromatic ring,
optionally substituted arylsulfone, optionally substituted
5-membered heteroaryl ring, --N(R')(R'),
--(CH.sub.2).sub.2N(R')(R'), or --(CH.sub.2)N(R')(R').
[0076] In one embodiment of Ar.sub.1 in formula a-i, ring A.sub.1
is a phenyl ring, m is 1, and WR.sup.W is independently optionally
substituted pyrrolidine or piperidine.
[0077] In some embodiments, m is 0. Or, m is 1. Or, m is 2. In some
embodiments, m is 3. In yet other embodiments, m is 4.
[0078] In one embodiment of the present invention, R.sup.1,
R.sup.2, R.sup.3, and R.sup.4 are simultaneously hydrogen.
[0079] In another embodiment of the present invention, k is 1 or 2
and each R.sup.1 is independently C1-C3 alkyl or C3-C6
cycloalkyl.
[0080] In one embodiment, k is 1 or 2, and each R.sup.1 is
halo.
[0081] In some embodiments, X is a bond or is an optionally
substituted C.sub.1-6 alkylidene chain wherein one or two
non-adjacent methylene units are optionally and independently
replaced by O, NR', S, SO.sub.2, or COO, CO, and R.sup.X is R' or
halo. In still other embodiments, each occurrence of XR.sup.X is
independently --C.sub.1-3 alkyl, --O(C.sub.1-3alkyl), --CF.sub.3,
--OCF.sub.3, --SCF.sub.3, --F, --Cl, --Br, OH, --COOR', --COR',
--O(CH.sub.2).sub.2N(R')(R'), --O(CH.sub.2)N(R')(R'),
--CON(R')(R'), --(CH.sub.2).sub.2OR', --(CH.sub.2)OR', optionally
substituted phenyl, --N(R')(R'), --(CH.sub.2).sub.2N(R')(R'), or
--(CH.sub.2)N(R)(R').
[0082] In one embodiment, R.sup.1 is H, C1-C4 aliphatic, halo, or
C3-C6 cycloaliphatic.
[0083] In some embodiments, R.sup.4 is hydrogen. In certain other
embodiment, R.sup.4 is C.sub.1-4 straight or branched
aliphatic.
[0084] In some embodiments, R.sup.W is selected from halo, cyano,
CF.sub.3, CHF.sub.2, OCHF.sub.2, Me, Et, CH(Me).sub.2, CHMeEt,
n-propyl, t-butyl, OH, OMe, OEt, OPh, O-fluorophenyl,
O-difluorophenyl, O-methoxyphenyl, O-tolyl, O-benzyl, SMe,
SCF.sub.3, SCHF.sub.2, SEt, CH.sub.2CN, NH.sub.2, NHMe,
N(Me).sub.2, NHEt, N(Et).sub.2, C(O)CH.sub.3, C(O)Ph, C(O)NH.sub.2,
SPh, SO.sub.2-(amino-pyridyl), SO.sub.2NH.sub.2, SO.sub.2Ph,
SO.sub.2NHPh, SO.sub.2--N-morpholino, SO.sub.2--N-pyrrolidyl,
N-pyrrolyl, N-morpholino, 1-piperidyl, phenyl, benzyl,
(cyclohexyl-methylamino)methyl,
4-Methyl-2,4-dihydro-pyrazol-3-one-2-yl, benzimidazol-2yl,
furan-2-yl, 4-methyl-4H-[1,2,4]triazol-3-yl,
3-(4'-chlorophenyl)-[1,2,4]oxadiazol-5-yl, NHC(O)Me, NHC(O)Et,
NHC(O)Ph, NHSO.sub.2Me, 2-indolyl, 5-indolyl, --CH.sub.2CH.sub.2OH,
--OCF.sub.3, O-(2,3-dimethylphenyl), 5-methylfuryl,
--SO.sub.2--N-piperidyl, 2-tolyl, 3-tolyl, 4-tolyl, O-butyl,
NHCO.sub.2C(Me).sub.3, CO.sub.2C(Me).sub.3, isopropenyl, n-butyl,
O-(2,4-dichlorophenyl), NHSO.sub.2PhMe,
O-(3-chloro-5-trifluoromethyl-2-pyridyl), phenylhydroxymethyl,
2,5-dimethylpyrrolyl, NHCOCH.sub.2C(Me).sub.3,
O-(2-tert-butyl)phenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl,
4-hydroxymethyl phenyl, 4-dimethylaminophenyl,
2-trifluoromethylphenyl, 3-trifluoromethylphenyl,
4-trifluoromethylphenyl, 4-cyanomethylphenyl, 4-isobutylphenyl,
3-pyridyl, 4-pyridyl, 4-isopropylphenyl, 3-isopropylphenyl,
2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl,
3,4-methylenedioxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl,
4-ethoxyphenyl, 2-methylthiophenyl, 4-methylthiophenyl,
2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl,
3,4-dimethoxyphenyl, 5-chloro-2-methoxyphenyl, 2-OCF.sub.3-phenyl,
3-trifluoromethoxy-phenyl, 4-trifluoromethoxyphenyl,
2-phenoxyphenyl, 4-phenoxyphenyl, 2-fluoro-3-methoxy-phenyl,
2,4-dimethoxy-5-pyrimidyl, 5-isopropyl-2-methoxyphenyl,
2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-cyanophenyl,
3-chlorophenyl, 4-chlorophenyl, 2,3-difluorophenyl,
2,4-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl,
3,5-difluorophenyl, 3-chloro-4-fluoro-phenyl, 3,5-dichlorophenyl,
2,5-dichlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl,
2,4-dichlorophenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonyl
phenyl, 3-isopropyloxycarbonylphenyl, 3-acetamidophenyl,
4-fluoro-3-methylphenyl, 4-methanesulfinyl-phenyl,
4-methanesulfonyl-phenyl,
4-N-(2-N,N-dimethylaminoethyl)carbamoylphenyl, 5-acetyl-2-thienyl,
2-benzothienyl, 3-benzothienyl, furan-3-yl, 4-methyl-2-thienyl,
5-cyano-2-thienyl, N'-phenylcarbonyl-N-piperazinyl, --NHCO.sub.2Et,
--NHCO.sub.2Me, N-pyrrolidinyl,
--NHSO.sub.2(CH.sub.2).sub.2N-piperidine,
--NHSO.sub.2(CH.sub.2).sub.2N-morpholine,
--NHSO.sub.2(CH.sub.2).sub.2N(Me).sub.2,
COCH.sub.2N(Me)COCH.sub.2NHMe, --CO.sub.2Et, O-propyl,
--CH.sub.2CH.sub.2NHCO.sub.2C(Me).sub.3, aminomethyl, pentyl,
adamantyl, cyclopentyl, ethoxyethyl, C(Me).sub.2CH.sub.2OH,
C(Me).sub.2CO.sub.2Et, --CHOHMe, CH.sub.2CO.sub.2Et,
--C(Me).sub.2CH.sub.2NHCO.sub.2C(Me).sub.3, O(CH.sub.2).sub.2OEt,
O(CH.sub.2).sub.2OH, CO.sub.2Me, hydroxymethyl,
1-methyl-1-cyclohexyl, 1-methyl-1-cyclooctyl,
1-methyl-1-cycloheptyl, C(Et).sub.2C(Me).sub.3, C(Et).sub.3,
CONHCH.sub.2CH(Me).sub.2, 2-aminomethyl-phenyl, ethenyl,
1-piperidinylcarbonyl, ethynyl, cyclohexyl, 4-methylpiperidinyl,
--OCO.sub.2Me, --C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2CH(Me).sub.2,
--C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2CH.sub.2CH.sub.3,
--C(Me).sub.2CH.sub.2NHCO.sub.2Et,
--C(Me).sub.2CH.sub.2NHCO.sub.2Me,
--C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2C(Me).sub.3,
--CH.sub.2NHCOCF.sub.3, --CH.sub.2NHCO.sub.2C(Me).sub.3,
--C(Me).sub.2CH.sub.2NHCO.sub.2(CH.sub.2).sub.3CH.sub.3,
C(Me).sub.2CH.sub.2NHCO.sub.2(CH.sub.2).sub.2OMe,
C(OH)(CF.sub.3).sub.2,
--C(Me).sub.2CH.sub.2NHCO.sub.2CH.sub.2-tetrahydrofurane-3-yl,
C(Me).sub.2CH.sub.2O(CH.sub.2).sub.2OMe, or
3-ethyl-2,6-dioxopiperidin-3-yl.
[0085] In one embodiment, R' is hydrogen.
[0086] In one embodiment, R' is a C1-C8 aliphatic group, optionally
substituted with up to 3 substituents selected from halo, CN,
CF.sub.3, CHF.sub.2, OCF.sub.3, or OCHF.sub.2, wherein up to two
methylene units of said C1-C8 aliphatic is optionally replaced with
--CO--, --CONH(C1-C4 alkyl)-, --CO.sub.2--, --OCO--, --N(C1-C4
alkyl)CO.sub.2--, --O--, --N(C1-C4 alkyl)CON(C1-C4 alkyl)-,
--OCON(C1-C4 alkyl)-, --N(C1-C4 alkyl)CO--, --S--, --N(C1-C4
alkyl)-, --SO.sub.2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO.sub.2--, or
--N(C1-C4 alkyl)SO.sub.2N(C1-C4 alkyl)-.
[0087] In one embodiment, R' is a 3-8 membered saturated, partially
unsaturated, or fully unsaturated monocyclic ring having 0-3
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein R' is optionally substituted with up to 3
substituents selected from halo, CN, CF.sub.3, CHF.sub.2,
OCF.sub.3, OCHF.sub.2, or C1-C6 alkyl, wherein up to two methylene
units of said C1-C6 alkyl is optionally replaced with --CO--,
--CONH(C1-C4 alkyl)-, --CO.sub.2--, --OCO--, --N(C1-C4
alkyl)CO.sub.2--, --O--, --N(C1-C4 alkyl)CON(C1-C4 alkyl)-,
--OCON(C1-C4 alkyl)-, --N(C1-C4 alkyl)CO--, --S--, --N(C1-C4
alkyl)-, --SO.sub.2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO.sub.2--, or
--N(C1-C4 alkyl)SO.sub.2N(C1-C4 alkyl)-.
[0088] In one embodiment, R' is an 8-12 membered saturated,
partially unsaturated, or fully unsaturated bicyclic ring system
having 0-5 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; wherein R' is optionally substituted with up to
3 substituents selected from halo, CN, CF.sub.3, CHF.sub.2,
OCF.sub.3, OCHF.sub.2, or C1-C6 alkyl, wherein up to two methylene
units of said C1-C6 alkyl is optionally replaced with --CO--,
--CONH(C1-C4 alkyl)-, --CO.sub.2--, --OCO--, --N(C1-C4
alkyl)CO.sub.2--, --O--, --N(C1-C4 alkyl)CON(C1-C4 alkyl)-,
--OCON(C1-C4 alkyl)-, --N(C1-C4 alkyl)CO--, --S--, --N(C1-C4
alkyl)-, --SO.sub.2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO.sub.2--, or
--N(C1-C4 alkyl)SO.sub.2N(C1-C4 alkyl)-.
[0089] In one embodiment, two occurrences of R' are taken together
with the atom(s) to which they are bound to form an optionally
substituted 3-12 membered saturated, partially unsaturated, or
fully unsaturated monocyclic or bicyclic ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein R' is optionally substituted with up to 3
substituents selected from halo, CN, CF.sub.3, CHF.sub.2,
OCF.sub.3, OCHF.sub.2, or C1-C6 alkyl, wherein up to two methylene
units of said C1-C6 alkyl is optionally replaced with --CO--,
--CONH(C1-C4 alkyl)-, --CO.sub.2--, --OCO--, --N(C1-C4
alkyl)CO.sub.2--, --O--, --N(C1-C4 alkyl)CON(C1-C4 alkyl)-,
--OCON(C1-C4 alkyl)-, --N(C1-C4 alkyl)CO--, --S--, --N(C1-C4
alkyl)-, --SO.sub.2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO.sub.2--, or
--N(C1-C4 alkyl)SO.sub.2N(C1-C4 alkyl)-.
[0090] According to one embodiment, the present invention provides
compounds of formula IIA or formula IIA':
##STR00011##
[0091] According to one embodiment, the present invention provides
compounds of formula IIB or formula IIB':
##STR00012##
[0092] According to one embodiment, the present invention provides
compounds of formula IIIA or formula IIIA':
##STR00013##
wherein each of X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 is
independently selected from CH or N.
[0093] According to one embodiment, the present invention provides
compounds of formula IIIB or formula IIIB':
##STR00014##
wherein each of X.sub.1, X.sub.2, and X.sub.5 is independently
selected from CH or N.
[0094] According to one embodiment, the present invention provides
compounds of formula IIIC or formula IIIC':
##STR00015##
wherein each of X.sub.1, X.sub.2, and X.sub.3 is independently
selected from CH or N.
[0095] According to one embodiment, the present invention provides
compounds of formula IIID or formula IIID':
##STR00016##
wherein X.sub.5 is independently selected from CH or N and X.sub.6
is O, S, or NR'.
[0096] According to one embodiment, the present invention provides
compounds of formula IIIE or formula IIIE':
##STR00017##
wherein X.sub.5 is independently selected from CH or N and X.sub.6
is O, S, or NR'.
[0097] In some embodiments of formula IIIA or formula IIIA', each
of X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 is CH.
[0098] In some embodiments of formula IIIA or formula IIIA',
X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 taken together is
an optionally substituted ring selected from pyridyl, pyrazinyl, or
pyrimidinyl.
[0099] In some embodiments of formula IIIB, formula IIIB', formula
IIIC, or formula IIIC', X.sub.1, X.sub.2, X.sub.3, or X.sub.5 taken
together with ring A.sub.2 is an optionally substituted ring
selected from:
##STR00018## ##STR00019## ##STR00020## ##STR00021## ##STR00022##
##STR00023## ##STR00024##
[0100] In some embodiments, R.sup.W is selected from R'halo, cyano,
CF.sub.3, CHF.sub.2, OCHF.sub.2, Me, Et, CH(Me).sub.2, CHMeEt,
n-propyl, t-butyl, OH, OMe, OEt, OPh, O-fluorophenyl,
O-difluorophenyl, O-methoxyphenyl, O-tolyl, O-benzyl, SMe,
SCF.sub.3, SCHF.sub.2, SEt, CH.sub.2CN, NH.sub.2, NHMe,
N(Me).sub.2, NHEt, N(Et).sub.2, C(O)CH.sub.3, C(O)Ph, C(O)NH.sub.2,
SPh, SO.sub.2-(amino-pyridyl), SO.sub.2NH.sub.2, SO.sub.2Ph,
SO.sub.2NHPh, SO.sub.2--N-morpholino, SO.sub.2--N-pyrrolidyl,
N-pyrrolyl, N-morpholino, 1-piperidyl, phenyl, benzyl,
(cyclohexyl-methylamino)methyl,
4-Methyl-2,4-dihydro-pyrazol-3-one-2-yl, benzimidazol-2yl,
furan-2-yl, 4-methyl-4H-[1,2,4]triazol-3-yl,
3-(4'-chlorophenyl)-[1,2,4]oxadiazol-5-yl, NHC(O)Me, NHC(O)Et,
NHC(O)Ph, or NHSO.sub.2Me.
[0101] In some embodiments, X and R.sup.X, taken together, is Me,
Et, halo, CN, CF.sub.3, OH, OMe, OEt, SO.sub.2N(Me)(fluorophenyl),
SO.sub.2-(4-methyl-piperidin-1-yl), or
SO.sub.2--N-pyrrolidinyl.
[0102] According to another embodiment, the present invention
provides compounds of formula IVA or formula IVA':
##STR00025##
[0103] According to another embodiment, the present invention
provides compounds of formula IVB or formula IVB':
##STR00026##
[0104] According to another embodiment, the present invention
provides compounds of formula IVC or formula IVC':
##STR00027##
[0105] In one embodiment, the present invention provides compounds
of formula IVA, formula IVA', formula IVB, formula IVB', formula
IVC, or formula IVC', wherein k is 1 or 2, and R.sup.1 is H, Me, or
halo. In another embodiment, k is 1 and R.sup.1 is Me. In another
embodiment, k is 2, and R.sup.1 is Me.
[0106] In one embodiment, the present invention provides compounds
of formula IVB, formula IVB', formula IVC, or formula IVC', wherein
ring A.sub.2 is an optionally substituted, saturated, unsaturated,
or aromatic seven membered ring with 0-3 heteroatoms selected from
O, S, or N. Exemplary rings include azepanyl, 5,5-dimethyl
azepanyl, etc.
[0107] In one embodiment, the present invention provides compounds
of formula IVB, formula IVB', formula IVC, or formula IVC', wherein
ring A.sub.2 is an optionally substituted, saturated, unsaturated,
or aromatic six membered ring with 0-3 heteroatoms selected from O,
S, or N. Exemplary rings include piperidinyl,
4,4-dimethylpiperidinyl, etc.
[0108] In one embodiment, the present invention provides compounds
of formula IVB, formula IVB', formula IVC, or formula IVC', wherein
ring A.sub.2 is an optionally substituted, saturated, unsaturated,
or aromatic five membered ring with 0-3 heteroatoms selected from
O, S, or N.
[0109] In one embodiment, the present invention provides compounds
of formula IVB, formula IVB', formula IVC, or formula IVC', wherein
ring A.sub.2 is an optionally substituted five membered ring with
one nitrogen atom, e.g., pyrrolyl or pyrrolidinyl.
[0110] According to one embodiment of formula IVA, the following
compound of formula VA-1 or formula VA-1' is provided:
##STR00028##
[0111] wherein each of WR.sup.W2 and WR.sup.W4 is independently
selected from hydrogen, CN, CF.sub.3, OCF.sub.3, halo, C1-C6
straight or branched alkyl, 3-12 membered cycloaliphatic, phenyl,
C5-C10 heteroaryl or C3-C7 heterocyclic, wherein said heteroaryl or
heterocyclic has up to 3 heteroatoms selected from O, S, or N,
wherein said WR.sup.W2 and WR.sup.W4 is independently and
optionally substituted with up to three substituents selected from
--OR', --CF.sub.3, --OCF.sub.3, SR', S(O)R', SO.sub.2R',
--SCF.sub.3, halo, CN, --COOR', --COR',
--O(CH.sub.2).sub.2N(R')(R'), --O(CH.sub.2)N(R')(R'),
--CON(R')(R'), --(CH.sub.2).sub.2OR', --(CH.sub.2)OR', CH.sub.2CN,
optionally substituted phenyl or phenoxy, --N(R')(R'),
--NR'C(O)OR', --NR'C(O)R', --(CH.sub.2).sub.2N(R')(R'), or
--(CH.sub.2)N(R')(R'); and
[0112] WR.sup.W5 is selected from hydrogen, halo, --OH, NH.sub.2,
CN, CHF.sub.2, NHR', N(R').sub.2, --NHC(O)R', --NHC(O)OR',
NHSO.sub.2R', --OR', CH.sub.2OH, CH.sub.2N(R').sub.2, C(O)OR',
C(O)N(R').sub.2, SO.sub.2NHR', SO.sub.2N(R').sub.2,
OSO.sub.2N(R').sub.2, OSO.sub.2CF.sub.3, or CH.sub.2NHC(O)OR'. Or,
WR.sup.W4 and WR.sup.W5 taken together form a 5-7 membered ring
containing 0-3 three heteroatoms selected from N, O, or S, wherein
said ring is optionally substituted with up to three WR.sup.W
substituents.
[0113] In one embodiment, the present invention provides compounds
of formula VA-1 or formula VA-1', wherein k is 0.
[0114] In another embodiment, the present invention provides
compounds of formula VA-2 or formula VA-2':
##STR00029##
wherein:
[0115] ring B is a 5-7 membered monocyclic or bicyclic,
heterocyclic or heteroaryl ring optionally substituted with up to n
occurrences of -Q-R.sup.Q;
[0116] Q is W;
[0117] R.sup.Q is R.sup.W;
[0118] m is 0-4;
[0119] n is 0-4; and
[0120] R.sup.1, k, W, and R.sup.W are as defined above.
[0121] In one embodiment, m is 0-2. Or, m is 0. Or m is 1.
[0122] In one embodiment, n is 0-2. Or, n is 0. Or, n is 1.
[0123] In another embodiment, ring B is a 5-7 membered monocyclic,
heterocyclic ring having up to 2 heteroatoms selected from O, S, or
N, optionally substituted with up to n occurrences of -Q-R.sup.Q.
Exemplary heterocyclic rings include N-morpholinyl, N-piperidinyl,
4-benzoyl-piperazin-1-yl, pyrrolidin-1-yl, or
4-methyl-piperidin-1-yl.
[0124] In another embodiment, ring B is a 5-6 membered monocyclic,
heteroaryl ring having up to 2 heteroatoms selected from O, S, or
N, optionally substituted with up to n occurrences of -Q-R.sup.Q.
Exemplary such rings include benzimidazol-2-yl,
5-methyl-furan-2-yl, 2,5-dimethyl-pyrrol-1-yl, pyridine-4-yl,
indol-5-yl, indol-2-yl, 2,4-dimethoxy-pyrimidin-5-yl, furan-2-yl,
furan-3-yl, 2-acyl-thien-2-yl, benzothiophen-2-yl,
4-methyl-thien-2-yl, 5-cyano-thien-2-yl,
3-chloro-5-trifluoromethyl-pyridin-2-yl.
[0125] In another embodiment, the present invention provides
compounds of formula VA-3 or formula VA-3':
##STR00030##
wherein:
[0126] Q is W;
[0127] R.sup.Q is R.sup.W;
[0128] m is 0-4;
[0129] n is 0-4; and
[0130] R.sup.1, k, W, and R.sup.W are as defined above.
[0131] In one embodiment, n is 0-2.
[0132] In another embodiment, m is 0-2. In one embodiment, m is 0.
In one embodiment, m is 1. Or, m is 2.
[0133] In one embodiment, QR.sup.Q taken together is halo,
CF.sub.3, OCF.sub.3, CN, C1-C6 aliphatic, O--C1-C6 aliphatic,
O-phenyl, NH(C1-C6 aliphatic), or N(C1-C6 aliphatic).sub.2, wherein
said aliphatic and phenyl are optionally substituted with up to
three substituents selected from C1-C6 alkyl, O--C1-C6 alkyl, halo,
cyano, OH, or CF.sub.3, wherein up to two methylene units of said
C1-C6 aliphatic or C1-C6 alkyl is optionally replaced with --CO--,
--CONR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--,
--NR'CONR'--, --OCONR'--, --NR'CO--, --S--, --NR'--, SOR',
SO.sub.2R', --SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--.
In another embodiment, R' above is C1-C4 alkyl.
[0134] Exemplary QR.sup.Q include methyl, isopropyl, sec-butyl,
hydroxymethyl, CF.sub.3, NMe.sub.2, CN, CH.sub.2CN, fluoro, chloro,
OEt, OMe, SMe, OCF.sub.3, OPh, C(O)OMe, C(O)O-iPr, S(O)Me,
NHC(O)Me, or S(O).sub.2Me.
[0135] In another embodiment, the present invention provides
compounds of formula VB-1 or formula VB-1':
##STR00031##
wherein:
[0136] R.sup.w1 is hydrogen or C1-C6 aliphatic;
[0137] each of R.sup.W3 is hydrogen or C1-C6 aliphatic; or
[0138] both R.sup.W3 taken together form a C3-C6 cycloalkyl or
heterocyclic ring having up to two heteroatoms selected from O, S,
or NR', wherein said ring is optionally substituted with up to two
WR.sup.W substituents;
[0139] m is 0-4; and
[0140] k, R.sup.1, W, and R.sup.W are as defined above.
[0141] In one embodiment, WR.sup.w1 is hydrogen, C1-C6 aliphatic,
C(O)C1-C6 aliphatic, or C(O)OC1-C6 aliphatic.
[0142] In another embodiment, each R.sup.W3 is hydrogen, C1-C4
alkyl. Or, both R.sup.W3 taken together form a C3-C6 cycloaliphatic
ring or 5-7 membered heterocyclic ring having up to two heteroatoms
selected from O, S, or N, wherein said cycloaliphatic or
heterocyclic ring is optionally substituted with up to three
substitutents selected from WR.sup.W1. Exemplary such rings include
cyclopropyl, cyclopentyl, optionally substituted piperidyl,
etc.
[0143] In another embodiment, the present invention provides
compounds of formula VB-2 or formula VB-2':
##STR00032##
wherein:
[0144] ring A.sub.2 is a phenyl or a 5-6 membered heteroaryl ring,
wherein ring A.sub.2 and the phenyl ring fused thereto together
have up 4 substituents independently selected from WR.sup.W;
[0145] m is 0-4; and
[0146] W, R.sup.W, k, and R.sup.1 are as defined above.
[0147] In one embodiment, ring A.sub.2 is an optionally substituted
5-membered ring selected from pyrrolyl, furanyl, thienyl,
pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl,
oxadiazolyl, or triazolyl.
[0148] In one embodiment, ring A.sub.2 is an optionally substituted
5-membered ring selected from pyrrolyl, pyrazolyl, thiadiazolyl,
imidazolyl, oxazolyl, or triazolyl. Exemplary such rings
include:
##STR00033##
wherein said ring is optionally substituted as set forth above.
[0149] In another embodiment, ring A.sub.2 is an optionally
substituted 6-membered ring. Exemplary such rings include pyridyl,
pyrazinyl, or triazinyl. In another embodiment, said ring is an
optionally pyridyl.
[0150] In one embodiment, ring A.sub.2 is phenyl.
[0151] In another embodiment, ring A.sub.2 is pyrrolyl, pyrazolyl,
pyridyl, or thiadiazolyl.
[0152] Exemplary W in formula VB-2 or formula VB-2' includes a
bond, C(O), C(O)O or C1-C6 alkylene.
[0153] Exemplary R.sup.W in formula V-B-2 or formula V-B-2' include
cyano, halo, C1-C6 aliphatic, C3-C6 cycloaliphatic, aryl, 5-7
membered heterocyclic ring having up to two heteroatoms selected
from O, S, or N, wherein said aliphatic, phenyl, and heterocyclic
are independently and optionally substituted with up to three
substituents selected from C1-C6 alkyl, O--C1-C6 alkyl, halo,
cyano, OH, or CF.sub.3, wherein up to two methylene units of said
C1-C6 aliphatic or C1-C6 alkyl is optionally replaced with --CO--,
--CONR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--,
--NR'CONR'--, --OCONR'--, --NR'CO--, --S--, --NR'--,
--SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--. In another
embodiment, R' above is C1-C4 alkyl.
[0154] In one embodiment, the present invention provides compounds
of formula VB-3 or formula VB-3':
##STR00034##
wherein:
[0155] G.sub.4 is hydrogen, halo, CN, CF.sub.3, CHF.sub.2,
CH.sub.2F, optionally substituted C1-C6 aliphatic, aryl-C1-C6
alkyl, or a phenyl, wherein G.sub.4 is optionally substituted with
up to 4 WR.sup.W substituents; wherein up to two methylene units of
said C1-C6 aliphatic or C1-C6 alkyl is optionally replaced with
--CO--, --CONR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--,
--NR'CONR'--, --OCONR'--, --NR'CO--, --S--, --NR'--,
--SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--;
[0156] G.sub.5 is hydrogen, an optionally substituted C1-C6
aliphatic, CF.sub.3, or CN; wherein said indole ring system is
further optionally substituted with up to 3 substituents
independently selected from WR.sup.W.
[0157] In one embodiment, G.sub.4 is hydrogen. Or, G.sub.5 is
hydrogen.
[0158] In another embodiment, G.sub.4 is hydrogen, and G.sub.5 is
C1-C6 aliphatic, CF.sub.3, or CN, wherein said aliphatic is
optionally substituted with C1-C6 alkyl, halo, cyano, or CF.sub.3,
and wherein up to two methylene units of said C1-C6 aliphatic or
C1-C6 alkyl is optionally replaced with --CO--, --CONR'--,
--CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--, --NR'CONR'--,
--OCONR'--, --NR'CO--, --S--, --NR'--, --SO.sub.2NR'--,
NR'SO.sub.2--, or --NR'SO.sub.2NR'--. In another embodiment, R'
above is C1-C4 alkyl.
[0159] In another embodiment, G.sub.4 is hydrogen, and G.sub.5 is
cyano, CF.sub.3, methyl, ethyl, propyl, isopropyl, butyl,
sec-butyl, t-butyl, cyanomethyl, methoxyethyl, CH.sub.2C(O)OMe,
(CH.sub.2).sub.2--NHC(O)O-tert-butyl, or cyclopentyl.
[0160] In another embodiment, G.sub.5 is hydrogen, and G.sub.4 is
halo, C1-C6 aliphatic or phenyl, wherein said aliphatic or phenyl
is optionally substituted with C1-C6 alkyl, halo, cyano, or
CF.sub.3, wherein up to two methylene units of said C1-C6 aliphatic
or C1-C6 alkyl is optionally replaced with --CO--, --CONR'--,
--CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--, --NR'CONR'--,
--OCONR'--, --NR'CO--, --S--, --NR'--, --SO.sub.2NR'--,
NR'SO.sub.2--, or --NR'SO.sub.2NR'--. In another embodiment, R'
above is C1-C4 alkyl.
[0161] In another embodiment, G.sub.5 is hydrogen, and G.sub.4 is
halo, CF.sub.3, ethoxycarbonyl, t-butyl, 2-methoxyphenyl,
2-ethoxyphenyl, (4-C(O)NH(CH.sub.2).sub.2--NMe.sub.2)-phenyl,
2-methoxy-4-chloro-phenyl, pyridine-3-yl, 4-isopropylphenyl,
2,6-dimethoxyphenyl, sec-butylaminocarbonyl, ethyl, t-butyl, or
piperidin-1-ylcarbonyl.
[0162] In another embodiment, G.sub.4 and G.sub.5 are both
hydrogen, and the nitrogen ring atom of said indole ring is
substituted with C1-C6 aliphatic, C(O)(C1-C6 aliphatic), or benzyl,
wherein said aliphatic or benzyl is optionally substituted with
C1-C6 alkyl, halo, cyano, or CF.sub.3, wherein up to two methylene
units of said C1-C6 aliphatic or C1-C6 alkyl is optionally replaced
with --CO--, --CONR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--,
--O--, --NR'CONR'--, --OCONR'--, --NR'CO--, --S--, --NR'--,
--SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--. In another
embodiment, R' above is C1-C4 alkyl.
[0163] In another embodiment, G.sub.4 and G.sub.5 are both
hydrogen, and the nitrogen ring atom of said indole ring is
substituted with acyl, benzyl, C(O)CH.sub.2N(Me)C(O)CH.sub.2NHMe,
or ethoxycarbonyl.
[0164] Representative compounds of the present invention are set
forth below in Table 1 below.
TABLE-US-00001 TABLE 1 1 ##STR00035## 2 ##STR00036## 3 ##STR00037##
4 ##STR00038## 5 ##STR00039## 6 ##STR00040## 7 ##STR00041## 8
##STR00042## 9 ##STR00043## 10 ##STR00044## 11 ##STR00045## 12
##STR00046## 13 ##STR00047## 14 ##STR00048##
4. General Synthetic Schemes
[0165] Compounds of the present invention are readily prepared by
methods known in the art. Illustrated in the Examples hereinbelow
are exemplary methods for the preparation of compounds of the
present invention.
5. Uses, Formulation and Administration
[0166] Pharmaceutically Acceptable Compositions
[0167] As discussed above, the present invention provides compounds
that are useful as modulators of ABC transporters and thus are
useful in the treatment of disease, disorders or conditions such as
cystic fibrosis, hereditary emphysema, hereditary hemochromatosis,
coagulation-fibrinolysis deficiencies, such as protein C
deficiency, Type 1 hereditary angioedema, lipid processing
deficiencies, such as familial hypercholesterolemia, Type 1
chylomicronemia, abetalipoproteinemia, lysosomal storage diseases,
such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses,
Sandhof/Tay-Sachs, Crigler-Najjar type II,
polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron
dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism,
melanoma, glycanosis CDG type 1, congenital hyperthyroidism,
osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic
DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease,
neurodegenerative diseases such as Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, progressive supranuclear
plasy, Pick's disease, several polyglutamine neurological disorders
asuch as Huntington, spinocerebullar ataxia type I, spinal and
bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic
dystrophy, as well as spongiform encephalopathies, such as
hereditary Creutzfeldt-Jakob disease (due to prion protein
processing defect), Fabry disease, Straussler-Scheinker syndrome,
COPD, dry-eye disease, or Sjogren's disease.
[0168] Accordingly, in another aspect of the present invention,
pharmaceutically acceptable compositions are provided, wherein
these compositions comprise any of the compounds as described
herein, and optionally comprise a pharmaceutically acceptable
carrier, adjuvant or vehicle. In certain embodiments, these
compositions optionally further comprise one or more additional
therapeutic agents.
[0169] It will also be appreciated that certain of the compounds of
present invention can exist in free form for treatment, or where
appropriate, as a pharmaceutically acceptable derivative or a
prodrug thereof. According to the present invention, a
pharmaceutically acceptable derivative or a prodrug includes, but
is not limited to, pharmaceutically acceptable salts, esters, salts
of such esters, or any other adduct or derivative which upon
administration to a patient in need thereof is capable of
providing, directly or indirectly, a compound as otherwise
described herein, or a metabolite or residue thereof.
[0170] As used herein, the term "pharmaceutically acceptable salt"
refers to those salts which are, within the scope of sound medical
judgement, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. A "pharmaceutically acceptable salt" means any
non-toxic salt or salt of an ester of a compound of this invention
that, upon administration to a recipient, is capable of providing,
either directly or indirectly, a compound of this invention or an
inhibitorily active metabolite or residue thereof.
[0171] Pharmaceutically acceptable salts are well known in the art.
For example, S. M. Berge, et al. describe pharmaceutically
acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66,
1-19, incorporated herein by reference. Pharmaceutically acceptable
salts of the compounds of this invention include those derived from
suitable inorganic and organic acids and bases. Examples of
pharmaceutically acceptable, nontoxic acid addition salts are salts
of an amino group formed with inorganic acids such as hydrochloric
acid, hydrobromic acid, phosphoric acid, sulfuric acid and
perchloric acid or with organic acids such as acetic acid, oxalic
acid, maleic acid, tartaric acid, citric acid, succinic acid or
malonic acid or by using other methods used in the art such as ion
exchange. Other pharmaceutically acceptable salts include adipate,
alginate, ascorbate, aspartate, benzenesulfonate, benzoate,
bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N.sup.+(C.sub.1-4alkyl).sub.4 salts. This
invention also envisions the quaternization of any basic
nitrogen-containing groups of the compounds disclosed herein. Water
or oil-soluble or dispersable products may be obtained by such
quaternization. Representative alkali or alkaline earth metal salts
include sodium, lithium, potassium, calcium, magnesium, and the
like. Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine
cations formed using counterions such as halide, hydroxide,
carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and
aryl sulfonate.
[0172] As described above, the pharmaceutically acceptable
compositions of the present invention additionally comprise a
pharmaceutically acceptable carrier, adjuvant, or vehicle, which,
as used herein, includes any and all solvents, diluents, or other
liquid vehicle, dispersion or suspension aids, surface active
agents, isotonic agents, thickening or emulsifying agents,
preservatives, solid binders, lubricants and the like, as suited to
the particular dosage form desired. Remington's Pharmaceutical
Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co.,
Easton, Pa., 1980) discloses various carriers used in formulating
pharmaceutically acceptable compositions and known techniques for
the preparation thereof. Except insofar as any conventional carrier
medium is incompatible with the compounds of the invention, such as
by producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other component(s) of
the pharmaceutically acceptable composition, its use is
contemplated to be within the scope of this invention. Some
examples of materials which can serve as pharmaceutically
acceptable carriers include, but are not limited to, ion
exchangers, alumina, aluminum stearate, lecithin, serum proteins,
such as human serum albumin, buffer substances such as phosphates,
glycine, sorbic acid, or potassium sorbate, partial glyceride
mixtures of saturated vegetable fatty acids, water, salts or
electrolytes, such as protamine sulfate, disodium hydrogen
phosphate, potassium hydrogen phosphate, sodium chloride, zinc
salts, colloidal silica, magnesium trisilicate, polyvinyl
pyrrolidone, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, wool fat, sugars such
as lactose, glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil; safflower oil; sesame oil; olive oil; corn oil and soybean
oil; glycols; such a propylene glycol or polyethylene glycol;
esters such as ethyl oleate and ethyl laurate; agar; buffering
agents such as magnesium hydroxide and aluminum hydroxide; alginic
acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as sodium lauryl sulfate and magnesium
stearate, as well as coloring agents, releasing agents, coating
agents, sweetening, flavoring and perfuming agents, preservatives
and antioxidants can also be present in the composition, according
to the judgment of the formulator.
[0173] Uses of Compounds and Pharmaceutically Acceptable
Compositions
[0174] In yet another aspect, the present invention provides a
method of treating a condition, disease, or disorder implicated by
ABC transporter activity, e.g., CFTR. In certain embodiments, the
present invention provides a method of treating a condition,
disease, or disorder implicated by a deficiency of the ABC
transporter activity, the method comprising administering a
composition comprising a compound of formula (I) to a subject,
preferably a mammal, in need thereof.
[0175] In certain embodiments, the present invention provides a
method of treating cystic fibrosis, hereditary emphysema,
hereditary hemochromatosis, coagulation-fibrinolysis deficiencies,
such as protein C deficiency, Type 1 hereditary angioedema, lipid
processing deficiencies, such as familial hypercholesterolemia,
Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage
diseases, such as I-cell disease/pseudo-Hurler,
mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II,
polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron
dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism,
melanoma, glycanosis CDG type 1, congenital hyperthyroidism,
osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic
DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease,
neurodegenerative diseases such as Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, progressive supranuclear
plasy, Pick's disease, several polyglutamine neurological disorders
asuch as Huntington, spinocerebullar ataxia type I, spinal and
bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic
dystrophy, as well as spongiform encephalopathies, such as
hereditary Creutzfeldt-Jakob disease (due to prion protein
processing defect), Fabry disease, Straussler-Scheinker syndrome,
COPD, dry-eye disease, or Sjogren's disease, comprising the step of
administering to said mammal an effective amount of a composition
comprising a compound of the present invention.
[0176] According to an alternative preferred embodiment, the
present invention provides a method of treating cystic fibrosis
comprising the step of administering to said mammal a composition
comprising the step of administering to said mammal an effective
amount of a composition comprising a compound of the present
invention.
[0177] According to the invention an "effective amount" of the
compound or pharmaceutically acceptable composition is that amount
effective for treating or lessening the severity of one or more of
cystic fibrosis, hereditary emphysema, hereditary hemochromatosis,
coagulation-fibrinolysis deficiencies, such as protein C
deficiency, Type 1 hereditary angioedema, lipid processing
deficiencies, such as familial hypercholesterolemia, Type 1
chylomicronemia, abetalipoproteinemia, lysosomal storage diseases,
such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses,
Sandhof/Tay-Sachs, Crigler-Najjar type II,
polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron
dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism,
melanoma, glycanosis CDG type 1, congenital hyperthyroidism,
osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic
DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease,
neurodegenerative diseases such as Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, progressive supranuclear
plasy, Pick's disease, several polyglutamine neurological disorders
asuch as Huntington, spinocerebullar ataxia type I, spinal and
bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic
dystrophy, as well as spongiform encephalopathies, such as
hereditary Creutzfeldt-Jakob disease (due to prion protein
processing defect), Fabry disease, Straussler-Scheinker syndrome,
COPD, dry-eye disease, or Sjogren's disease.
[0178] The compounds and compositions, according to the method of
the present invention, may be administered using any amount and any
route of administration effective for treating or lessening the
severity of one or more of cystic fibrosis, hereditary emphysema,
hereditary hemochromatosis, coagulation-fibrinolysis deficiencies,
such as protein C deficiency, Type 1 hereditary angioedema, lipid
processing deficiencies, such as familial hypercholesterolemia,
Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage
diseases, such as I-cell disease/pseudo-Hurler,
mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II,
polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron
dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism,
melanoma, glycanosis CDG type 1, congenital hyperthyroidism,
osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT
deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic
DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease,
neurodegenerative diseases such as Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, progressive supranuclear
plasy, Pick's disease, several polyglutamine neurological disorders
asuch as Huntington, spinocerebullar ataxia type I, spinal and
bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic
dystrophy, as well as spongiform encephalopathies, such as
hereditary Creutzfeldt-Jakob disease (due to prion protein
processing defect), Fabry disease, Straussler-Scheinker syndrome,
COPD, dry-eye disease, or Sjogren's disease.
[0179] In one embodiment, the compounds and compositions of the
present invention are useful for treating or lessening the severity
of cystic fibrosis in a patient.
[0180] In certain embodiments, the compounds and compositions of
the present invention are useful for treating or lessening the
severity of cystic fibrosis in patients who exhibit residual CFTR
activity in the apical membrane of respiratory and non-respiratory
epithelia. The presence of residual CFTR activity at the epithelial
surface can be readily detected using methods known in the art,
e.g., standard electrophysiological, biochemical, or histochemical
techniques. Such methods identify CFTR activity using in vivo or ex
vivo electrophysiological techniques, measurement of sweat or
salivary Cl.sup.- concentrations, or ex vivo biochemical or
histochemical techniques to monitor cell surface density. Using
such methods, residual CFTR activity can be readily detected in
patients heterozygous or homozygous for a variety of different
mutations, including patients homozygous or heterozygous for the
most common mutation, .DELTA.F508.
[0181] In another embodiment, the compounds and compositions of the
present invention are useful for treating or lessening the severity
of cystic fibrosis in patients who have residual CFTR activity
induced or augmented using pharmacological methods or gene therapy.
Such methods increase the amount of CFTR present at the cell
surface, thereby inducing a hitherto absent CFTR activity in a
patient or augmenting the existing level of residual CFTR activity
in a patient.
[0182] In one embodiment, the compounds and compositions of the
present invention are useful for treating or lessening the severity
of cystic fibrosis in patients within certain genotypes exhibiting
residual CFTR activity, e.g., class III mutations (impaired
regulation or gating), class IV mutations (altered conductance), or
class V mutations (reduced synthesis) (Lee R. Choo-Kang, Pamela L.,
Zeitlin, Type I, II, III, IV, and V cystic fibrosis Tansmembrane
Conductance Regulator Defects and Opportunities of Therapy; Current
Opinion in Pulmonary Medicine 6:521-529, 2000). Other patient
genotypes that exhibit residual CFTR activity include patients
homozygous for one of these classes or heterozygous with any other
class of mutations, including class I mutations, class II
mutations, or a mutation that lacks classification.
[0183] In one embodiment, the compounds and compositions of the
present invention are useful for treating or lessening the severity
of cystic fibrosis in patients within certain clinical phenotypes,
e.g., a moderate to mild clinical phenotype that typically
correlates with the amount of residual CFTR activity in the apical
membrane of epithelia. Such phenotypes include patients exhibiting
pancreatic sufficiency or patients diagnosed with idiopathic
pancreatitis and congenital bilateral absence of the vas deferens,
or mild lung disease.
[0184] The exact amount required will vary from subject to subject,
depending on the species, age, and general condition of the
subject, the severity of the infection, the particular agent, its
mode of administration, and the like. The compounds of the
invention are preferably formulated in dosage unit form for ease of
administration and uniformity of dosage. The expression "dosage
unit form" as used herein refers to a physically discrete unit of
agent appropriate for the patient to be treated. It will be
understood, however, that the total daily usage of the compounds
and compositions of the present invention will be decided by the
attending physician within the scope of sound medical judgment. The
specific effective dose level for any particular patient or
organism will depend upon a variety of factors including the
disorder being treated and the severity of the disorder; the
activity of the specific compound employed; the specific
composition employed; the age, body weight, general health, sex and
diet of the patient; the time of administration, route of
administration, and rate of excretion of the specific compound
employed; the duration of the treatment; drugs used in combination
or coincidental with the specific compound employed, and like
factors well known in the medical arts. The term "patient", as used
herein, means an animal, preferably a mammal, and most preferably a
human.
[0185] The pharmaceutically acceptable compositions of this
invention can be administered to humans and other animals orally,
rectally, parenterally, intracisternally, intravaginally,
intraperitoneally, topically (as by powders, ointments, or drops),
bucally, as an oral or nasal spray, or the like, depending on the
severity of the infection being treated. In certain embodiments,
the compounds of the invention may be administered orally or
parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg
and preferably from about 1 mg/kg to about 25 mg/kg, of subject
body weight per day, one or more times a day, to obtain the desired
therapeutic effect.
[0186] Liquid dosage forms for oral administration include, but are
not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0187] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0188] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0189] In order to prolong the effect of a compound of the present
invention, it is often desirable to slow the absorption of the
compound from subcutaneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or
amorphous material with poor water solubility. The rate of
absorption of the compound then depends upon its rate of
dissolution that, in turn, may depend upon crystal size and
crystalline form. Alternatively, delayed absorption of a
parenterally administered compound form is accomplished by
dissolving or suspending the compound in an oil vehicle. Injectable
depot forms are made by forming microencapsule matrices of the
compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of compound to
polymer and the nature of the particular polymer employed, the rate
of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or microemulsions that are
compatible with body tissues.
[0190] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0191] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0192] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes. Solid
compositions of a similar type may also be employed as fillers in
soft and hard-filled gelatin capsules using such excipients as
lactose or milk sugar as well as high molecular weight polethylene
glycols and the like.
[0193] The active compounds can also be in microencapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose or starch. Such dosage forms may also comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents. They may optionally contain opacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
substances and waxes.
[0194] Dosage forms for topical or transdermal administration of a
compound of this invention include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, eardrops, and
eye drops are also contemplated as being within the scope of this
invention. Additionally, the present invention contemplates the use
of transdermal patches, which have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
are prepared by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0195] As described generally above, the compounds of the invention
are useful as modulators of ABC transporters. Thus, without wishing
to be bound by any particular theory, the compounds and
compositions are particularly useful for treating or lessening the
severity of a disease, condition, or disorder where hyperactivity
or inactivity of ABC transporters is implicated in the disease,
condition, or disorder. When hyperactivity or inactivity of an ABC
transporter is implicated in a particular disease, condition, or
disorder, the disease, condition, or disorder may also be referred
to as a "ABC transporter-mediated disease, condition or disorder".
Accordingly, in another aspect, the present invention provides a
method for treating or lessening the severity of a disease,
condition, or disorder where hyperactivity or inactivity of an ABC
transporter is implicated in the disease state.
[0196] The activity of a compound utilized in this invention as a
modulator of an ABC transporter may be assayed according to methods
described generally in the art and in the Examples herein.
[0197] It will also be appreciated that the compounds and
pharmaceutically acceptable compositions of the present invention
can be employed in combination therapies, that is, the compounds
and pharmaceutically acceptable compositions can be administered
concurrently with, prior to, or subsequent to, one or more other
desired therapeutics or medical procedures. The particular
combination of therapies (therapeutics or procedures) to employ in
a combination regimen will take into account compatibility of the
desired therapeutics and/or procedures and the desired therapeutic
effect to be achieved. It will also be appreciated that the
therapies employed may achieve a desired effect for the same
disorder (for example, an inventive compound may be administered
concurrently with another agent used to treat the same disorder),
or they may achieve different effects (e.g., control of any adverse
effects). As used herein, additional therapeutic agents that are
normally administered to treat or prevent a particular disease, or
condition, are known as "appropriate for the disease, or condition,
being treated".
[0198] In one embodiment, the additional agent is selected from a
mucolytic agent, bronchodialator, an anti-biotic, an anti-infective
agent, an anti-inflammatory agent, a CFTR modulator other than a
compound of the present invention, or a nutritional agent.
[0199] The amount of additional therapeutic agent present in the
compositions of this invention will be no more than the amount that
would normally be administered in a composition comprising that
therapeutic agent as the only active agent. Preferably the amount
of additional therapeutic agent in the presently disclosed
compositions will range from about 50% to 100% of the amount
normally present in a composition comprising that agent as the only
therapeutically active agent.
[0200] The compounds of this invention or pharmaceutically
acceptable compositions thereof may also be incorporated into
compositions for coating an implantable medical device, such as
prostheses, artificial valves, vascular grafts, stents and
catheters. Accordingly, the present invention, in another aspect,
includes a composition for coating an implantable device comprising
a compound of the present invention as described generally above,
and in classes and subclasses herein, and a carrier suitable for
coating said implantable device. In still another aspect, the
present invention includes an implantable device coated with a
composition comprising a compound of the present invention as
described generally above, and in classes and subclasses herein,
and a carrier suitable for coating said implantable device.
Suitable coatings and the general preparation of coated implantable
devices are described in U.S. Pat. Nos. 6,099,562; 5,886,026; and
5,304,121. The coatings are typically biocompatible polymeric
materials such as a hydrogel polymer, polymethyldisiloxane,
polycaprolactone, polyethylene glycol, polylactic acid, ethylene
vinyl acetate, and mixtures thereof. The coatings may optionally be
further covered by a suitable topcoat of fluorosilicone,
polysaccarides, polyethylene glycol, phospholipids or combinations
thereof to impart controlled release characteristics in the
composition.
[0201] Another aspect of the invention relates to modulating ABC
transporter activity in a biological sample or a patient (e.g., in
vitro or in vivo), which method comprises administering to the
patient, or contacting said biological sample with a compound of
formula I or a composition comprising said compound. The term
"biological sample", as used herein, includes, without limitation,
cell cultures or extracts thereof; biopsied material obtained from
a mammal or extracts thereof; and blood, saliva, urine, feces,
semen, tears, or other body fluids or extracts thereof.
[0202] Modulation of ABC transporter activity, e.g., CFTR, in a
biological sample is useful for a variety of purposes that are
known to one of skill in the art. Examples of such purposes
include, but are not limited to, the study of ABC transporters in
biological and pathological phenomena; and the comparative
evaluation of new modulators of ABC transporters.
[0203] In yet another embodiment, a method of modulating activity
of an anion channel in vitro or in vivo, is provided comprising the
step of contacting said channel with a compound of formula (I). In
preferred embodiments, the anion channel is a chloride channel or a
bicarbonate channel. In other preferred embodiments, the anion
channel is a chloride channel.
[0204] According to an alternative embodiment, the present
invention provides a method of increasing the number of functional
ABC transporters in a membrane of a cell, comprising the step of
contacting said cell with a compound of formula (I). The term
"functional ABC transporter" as used herein means an ABC
transporter that is capable of transport activity. In preferred
embodiments, said functional ABC transporter is CFTR.
[0205] According to another preferred embodiment, the activity of
the ABC transporter is measured by measuring the transmembrane
voltage potential. Means for measuring the voltage potential across
a membrane in the biological sample may employ any of the known
methods in the art, such as optical membrane potential assay or
other electrophysiological methods.
[0206] The optical membrane potential assay utilizes
voltage-sensitive FRET sensors described by Gonzalez and Tsien (See
Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by
fluorescence resonance energy transfer in single cells" Biophys J
69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997)
"Improved indicators of cell membrane potential that use
fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in
combination with instrumentation for measuring fluorescence changes
such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E.,
K. Oades, et al. (1999) "Cell-based assays and instrumentation for
screening ion-channel targets" Drug Discov Today 4(9):
431-439).
[0207] These voltage sensitive assays are based on the change in
fluorescence resonant energy transfer (FRET) between the
membrane-soluble, voltage-sensitive dye, DiSBAC.sub.2(3), and a
fluorescent phospholipid, CC2-DMPE, which is attached to the outer
leaflet of the plasma membrane and acts as a FRET donor. Changes in
membrane potential (V.sub.m) cause the negatively charged
DiSBAC.sub.2(3) to redistribute across the plasma membrane and the
amount of energy transfer from CC2-DMPE changes accordingly. The
changes in fluorescence emission can be monitored using VIPR.TM.
II, which is an integrated liquid handler and fluorescent detector
designed to conduct cell-based screens in 96- or 384-well
microtiter plates.
[0208] In another aspect the present invention provides a kit for
use in measuring the activity of a ABC transporter or a fragment
thereof in a biological sample in vitro or in vivo comprising (i) a
composition comprising a compound of formula (I) or any of the
above embodiments; and (ii) instructions for a) contacting the
composition with the biological sample and b) measuring activity of
said ABC transporter or a fragment thereof. In one embodiment, the
kit further comprises instructions for a) contacting an additional
composition with the biological sample; b) measuring the activity
of said ABC transporter or a fragment thereof in the presence of
said additional compound, and c) comparing the activity of the ABC
transporter in the presence of the additional compound with the
density of the ABC transporter in the presence of a composition of
formula (I). In preferred embodiments, the kit is used to measure
the density of CFTR.
[0209] In order that the invention described herein may be more
fully understood, the following examples are set forth. It should
be understood that these examples are for illustrative purposes
only and are not to be construed as limiting this invention in any
manner.
EXAMPLES
General Scheme
##STR00049##
[0210] Example
##STR00050##
[0211] Diethyl 2-((thiophen-3-ylamino)methylene)malonate 2
[0212] A mixture of methyl 3-aminothiophene-2-carboxylate 1 (5.0 g,
32 mmol, 1.0 eq), N-methyl piperazine (6.5 g, 64 mmol, 2.0 eq) and
NMP (30 mL) was heated to reflux for 16 hours. After the
decarboxylation was complete, the reaction mixture was allowed to
cool to room temperature and diethyl 2-(ethoxymethylene)-malonate
(7.0 g, 32 mmol, 2.0 eq) was added. The reaction mixture was heated
to reflux for 4 h. The product was purified using SiO.sub.2 column
chromatography (Hex/EtOAc; 100:0 to 80:20%) to obtain a light
yellow powder, 5.0 g (31%). LC/MS (10-99% CH.sub.3CN/0.05% TFA
gradient over 5 min): m/z 270.2, retention time 1.52 minutes.
.sup.1H NMR (DMSO-d.sub.6) .delta.: 10.80 (d, 1.0H, J=13.87 Hz,
NH), 8.30 (d, 1.0H, J=13.94 Hz), 7.60 (dd, 1.0 H, J=3.0 Hz, J'=2.0
Hz), 7.40 (dd, 1.0H, J=1.5 Hz, J'=3.13 Hz), 7.28 (dd, 1.0H, J=1.5
Hz, J'=5.2 Hz), 4.20 (q, 2H, J=7.0 Hz), 4.10 (q, 2H, J=7.0 Hz),
1.30 (m, 6H).
Ethyl 7-hydroxythieno[3,2-b]pyridine-6-carboxylate 3
[0213] The diethyl 2-((thiophen-3-ylamino)methylene)malonate 2 (1.0
g, 3.7 mmol, 1 eq) was heated to 240.degree. C. in Ph.sub.2O (10
mL) for 6 h. After the starting material was consumed, the reaction
mixture was allowed to cool to room temperature and solid was
filtered. The solid was washed with water and dichloromethane to
obtain the desired compound as a light brown powder (0.42 g 50%
yield). LC/MS (10-99% CH.sub.3CN/0.05% TFA gradient over 5 min):
m/z 224.0, retention time 0.40 minutes. .sup.1H NMR (DMSO-d.sub.6)
.delta.:12.80 (s, 1.0H), 8.50 (s, 1.0H), 8.05 (d, 1.0H, J=5.4 Hz),
7.30 (d, 1.0H, J=5.4 Hz), 4.20 (q, 2H, J=7.0 Hz), 4.10 (q, 2H,
J=7.0 Hz), 1.30 (t, 3H, J=7.0 Hz).
7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxylic acid 4
[0214] The ethyl 7-hydroxythieno[3,2-b]pyridine-6-carboxylate 3
(1.0 g, 4.5 mmol) was heated to reflux in 15% NaOH for 30 min.
After the reaction was completed it was allowed to cool to room
temperature and the solid was removed by filtration, washed with
water and ether to give the desired compound as an off-white powder
(0.6 g, 70% yield). LC/MS (10-99% CH.sub.3CN/0.05% TFA gradient
over 5 min): m/z 196.0, m/z 210.0, retention time 0.94 minutes.
.sup.1H NMR (DMSO-d.sub.6) .delta.: 15.50 (bs, 1.0H), 14.0 (s,
1.0H), 8.80 (s, 1.0H), 8.30 (d, 1.0H, J=5.4 Hz), 7.48 (d, 1.0H,
J=5.4 Hz).
[0215] Synthesis of Amine Precursor:
##STR00051##
[0216] a) SO.sub.2Cl.sub.2, R2=Cl; b) R2OH, R2=alkyl; c) NBS,
R1=Br; d) ClCO.sub.2R, TEA; e) HNO.sub.3, H.sub.2SO.sub.4; f) base;
g) ArB(OH).sub.2, R1=Br; h) [H]; I) R'X, R1=Br; j)
ClCF.sub.2CO.sub.2Me or FSO.sub.2CF.sub.2CO.sub.2Me/CuI; k) [H]; 1)
[H].
[0217] General Scheme:
##STR00052##
[0218] General Scheme:
##STR00053##
[0219] a) RX (X.dbd.Br,I), zinc triflate, TBAI, DIEA, toluene; b)
H.sub.2, Raney Ni, EtOH or SnCl.sub.2.2H.sub.2O, EtOH.
[0220] Specific Example:
##STR00054##
3-tert-Butyl-6-nitro-1H-indole
[0221] To a mixture of 6-nitroindole (1 g, 6.2 mmol), zinc triflate
(2.06 g, 5.7 mmol) and TBAI (1.7 g, 5.16 mmol) in anhydrous toluene
(11 mL) was added DIEA (1.47 g, 11.4 mmol) at room temperature
under nitrogen. The reaction mixture was stirred for 10 min at
120.degree. C., followed by addition of t-butyl bromide (0.707 g,
5.16 mmol). The resulting mixture was stirred for 45 min at
120.degree. C. The solid was filtered off and the filtrate was
concentrated to dryness and purified by column chromatography on
silica gel (Pet.Ether./EtOAc 20:1) to give
3-tert-butyl-6-nitro-1H-indole as a yellow solid (0.25 g, 19%).
.sup.1H NMR (CDCl.sub.3) .delta. 8.32 (d, J=2.1 Hz, 1H), 8.00 (dd,
J=2.1, 14.4 Hz, 1H), 7.85 (d, J=8.7 Hz, 1H), 7.25 (s, 1H), 1.46 (s,
9H).
B-11; 3-tert-Butyl-1H-indol-6-ylamine
[0222] A suspension of 3-tert-butyl-6-nitro-1H-indole (3.0 g, 13.7
mmol) and Raney Ni (0.5 g) in ethanol was stirred at room
temperature under H.sub.2 (1 atm) for 3 h. The catalyst was
filtered off and the filtrate was concentrated to dryness. The
residue was purified by column chromatography on silica gel
(Pet.Ether./EtOAc 4:1) to give 3-tert-butyl-1H-indol-6-ylamine
(B-11) (2.0 g, 77.3%) as a gray solid. .sup.1H NMR (CDCl.sub.3):
.delta. 7.58 (m, 2H), 6.73 (d, J=1.2 Hz, 1H), 6.66 (s, 1H), 6.57
(dd, J=0.8, 8.6 Hz, 1H), 3.60 (br s, 2H), 1.42 (s, 9H).
Example
##STR00055##
[0223] 2-Bromo-4-tert-butyl-phenylamine
[0224] To a solution of 4-tert-butyl-phenylamine (447 g, 3 mol) in
DMF (500 mL) was added dropwise NBS (531 g, 3 mol) in DMF (500 mL)
at room temperature. Upon completion, the reaction mixture was
diluted with water and extracted with EtOAc. The organic layer was
washed with water, brine, dried over Na.sub.2SO.sub.4 and
concentrated. The crude product was directly used in the next step
without further purification.
2-Bromo-4-tert-butyl-5-nitro-phenylamine
[0225] 2-Bromo-4-tert-butyl-phenylamine (162 g, 0.71 mol) was added
dropwise to H.sub.2SO.sub.4 (410 mL) at room temperature to yield a
clear solution. This clear solution was then cooled down to -5 to
-10.degree. C. A solution of KNO.sub.3 (82.5 g, 0.82 mol) in
H.sub.2SO.sub.4 (410 mL) was added dropwise while the temperature
was maintained between -5 to -10.degree. C. Upon completion, the
reaction mixture was poured into ice/water and extracted with
EtOAc. The combined organic layers were washed with 5%
Na.sub.2CO.sub.3 and brine, dried over Na.sub.2SO.sub.4 and
concentrated. The residue was purified by a column chromatography
(EtOAc/petroleum ether 1/10) to give
2-bromo-4-tert-butyl-5-nitro-phenylamine as a yellow solid (152 g,
78%).
4-tert-Butyl-5-nitro-2-trimethylsilanylethynyl-phenylamine
[0226] To a mixture of 2-bromo-4-tert-butyl-5-nitro-phenylamine
(27.3 g, 100 mmol) in toluene (200 mL) and water (100 mL) was added
Et.sub.3N (27.9 mL, 200 mmol), Pd(PPh.sub.3).sub.2Cl.sub.2 (2.11 g,
3 mmol), CuI (950 mg, 0.5 mmol) and trimethylsilyl acetylene (21.2
mL, 150 mmol) under a nitrogen atmosphere. The reaction mixture was
heated at 70.degree. C. in a sealed pressure flask for 2.5 h.,
cooled down to room temperature and filtered through a short plug
of Celite. The filter cake was washed with EtOAc. The combined
filtrate was washed with 5% NH.sub.4OH solution and water, dried
over Na.sub.2SO.sub.4 and concentrated. The crude product was
purified by column chromatography (0-10% EtOAc/petroleum ether) to
provide 4-tert-butyl-5-nitro-2-trimethylsilanylethynyl-phenylamine
as a brown viscous liquid (25 g, 81%).
5-tert-Butyl-6-nitro-1H-indole
[0227] To a solution of
4-tert-butyl-5-nitro-2-trimethylsilanylethynyl-phenylamine (25 g,
86 mmol) in DMF (100 mL) was added CuI (8.2 g, 43 mmol) under a
nitrogen atmosphere. The mixture was heated at 135.degree. C. in a
sealed pressure flask overnight, cooled down to room temperature
and filtered through a short plug of Celite. The filter cake was
washed with EtOAc. The combined filtrate was washed with water,
dried over Na.sub.2SO.sub.4 and concentrated. The crude product was
purified by column chromatography (10-20% EtOAc/Hexane) to provide
5-tert-butyl-6-nitro-1H-indole as a yellow solid (12.9 g, 69%).
B-24; 5-tert-Butyl-1H-indol-6-ylamine
[0228] Raney Ni (3 g) was added to 5-tert-butyl-6-nitro-1H-indole
(14.7 g, 67 mmol) in methanol (100 mL). The mixture was stirred
under hydrogen (1 atm) at 30.degree. C. for 3 h. The catalyst was
filtered off. The filtrate was dried over Na.sub.2SO.sub.4 and
concentrated. The crude dark brown viscous oil was purified by
column chromatography (10-20% EtOAc/petroleum ether) to give
5-tert-butyl-1H-indol-6-ylamine (B-24) as a gray solid (11 g, 87%).
.sup.1H NMR (300 MHz, DMSO-d6) .delta. 10.3 (br s, 1H), 7.2 (s,
1H), 6.9 (m, 1H), 6.6 (s, 1H), 6.1 (m, 1H), 4.4 (br s, 2H), 1.3 (s,
9H).
Example 4
General Scheme
##STR00056##
[0229] X.dbd.F, Cl; a) ROH, H.sub.2SO.sub.4 or MeSO.sub.3H,
CH.sub.2Cl.sub.2; b) R'CO.sub.2Cl, Et.sub.3N, 1,4-dioxane or
CHCl.sub.3; c) HNO.sub.3, H.sub.2SO.sub.4 or KNO.sub.3,
H.sub.2SO.sub.4 or HNO.sub.3, AcOH; d) piperidine,
CH.sub.2Cl.sub.2; e) HCO.sub.2NH.sub.4, Pd--C, EtOH or
SnCl.sub.2.2H.sub.2O, EtOH or H.sub.2, Pd--C, MeOH.
[0230] Specific Example
##STR00057##
2-tert-Butyl-4-fluorophenol
[0231] 4-Fluorophenol (5 g, 45 mmol) and tert-butanol (5.9 mL, 63
mmol) were dissolved in CH.sub.2Cl.sub.2 (80 mL) and treated with
concentrated sulfuric acid (98%, 3 mL). The mixture was stirred at
room temperature overnight. The organic layer was washed with
water, neutralized with NaHCO.sub.3, dried over MgSO.sub.4 and
concentrated. The residue was purified by column chromatography
(5-15% EtOAc-Hexane) to give 2-tert-butyl-4-fluorophenol (3.12 g,
42%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.32 (s, 1H),
6.89 (dd, J=11.1, 3.1 Hz, 1H), 6.84-6.79 (m, 1H), 6.74 (dd, J=8.7,
5.3 Hz, 1H), 1.33 (s, 9H).
2-tert-Butyl-4-fluorophenyl methyl carbonate
[0232] To a solution of 2-tert-butyl-4-fluorophenol (2.63 g, 15.7
mmol) and NEt.sub.3 (3.13 mL, 22.5 mmol) in dioxane (45 mL) was
added methyl chloroformate (1.27 mL, 16.5 mmol). The mixture was
stirred at room temperature for 1 h. The precipitate was removed
via filtration. The filtrate was then diluted with water and
extracted with ether. The ether extract was washed with water and
dried over MgSO.sub.4. After removal of solvent, the residue was
purified by column chromatography to give
2-tert-butyl-4-fluorophenyl methyl carbonate (2.08 g, 59%). .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 7.24 (dd, J=8.8, 5.4 Hz, 1H),
7.17-7.10 (m, 2H), 3.86 (s, 3H), 1.29 (s, 9H).
2-tert-Butyl-4-fluoro-5-nitrophenyl methyl carbonate (C-7-a) and
2-tert-butyl-4-fluoro-6-nitrophenyl methyl carbonate (C-6-a)
[0233] To a solution of 2-tert-butyl-4-fluorophenyl methyl
carbonate (1.81 g, 8 mmol) in H.sub.2SO.sub.4 (98%, 1 mL) was added
slowly a cooled mixture of H.sub.2SO.sub.4 (1 mL) and HNO.sub.3 (1
mL) at 0.degree. C. The mixture was stirred for 2 h while warming
to room temperature, poured into ice and extracted with diethyl
ether. The ether extract was washed with brine, dried over
MgSO.sub.4 and concentrated. The residue was purified by column
chromatography (0-10% EtOAc-Hexane) to give
2-tert-butyl-4-fluoro-5-nitrophenyl methyl carbonate (C-7-a) (1.2
g, 55%) and 2-tert-butyl-4-fluoro-6-nitrophenyl methyl carbonate
(C-6-a) (270 mg, 12%). 2-tert-Butyl-4-fluoro-5-nitrophenyl methyl
carbonate (C-7-a): .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.24
(d, J=7.1 Hz, 1H), 7.55 (d, J=13.4 Hz, 1H), 3.90 (s, 3H), 1.32 (s,
9H). 2-tert-butyl-4-fluoro-6-nitrophenyl methyl carbonate (C-6-a):
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.04 (dd, J=7.6, 3.1
Hz, 1H), 7.69 (dd, J=10.1, 3.1 Hz, 1H), 3.91 (s, 3H), 1.35 (s,
9H).
2-tert-Butyl-4-fluoro-5-nitrophenol
[0234] To a solution of 2-tert-butyl-4-fluoro-5-nitrophenyl methyl
carbonate (C-7-a) (1.08 g, 4 mmol) in CH.sub.2Cl.sub.2 (40 mL) was
added piperidine (3.94 mL, 10 mmol). The mixture was stirred at
room temperature for 1 h and extracted with 1N NaOH (3.times.). The
aqueous layer was acidified with 1N HCl and extracted with diethyl
ether. The ether extract was washed with brine, dried (MgSO.sub.4)
and concentrated to give 2-tert-butyl-4-fluoro-5-nitrophenol (530
mg, 62%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.40 (s,
1H), 7.49 (d, J=6.8 Hz, 1H), 7.25 (d, J=13.7 Hz, 1H), 1.36 (s,
9H).
C-7; 2-tert-Butyl-5-amino-4-fluorophenol
[0235] To a refluxing solution of
2-tert-butyl-4-fluoro-5-nitrophenol (400 mg, 1.88 mmol) and
ammonium formate (400 mg, 6.1 mmol) in EtOH (20 mL) was added 5%
Pd--C(260 mg). The mixture was refluxed for additional 1 h, cooled
and filtered through Celite. The solvent was removed by evaporation
to give 2-tert-butyl-5-amino-4-fluorophenol (C-7) (550 mg, 83%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.83 (br s, 1H), 6.66
(d, J=13.7 Hz, 1H), 6.22 (d, J=8.5 Hz, 1H), 4.74 (br s, 2H), 1.26
(s, 9H); HPLC ret. time 2.58 min, 10-99% CH.sub.3CN, 5 min run;
ESI-MS 184.0 m/z (MH.sup.+).
[0236] Analytical data for the compounds of Table 1 is shown
below:
TABLE-US-00002 Cmpd LC/MS LC/RT # M + 1 min NMR 1 378.5 1.43
.sup.1H NMR (DMSO-d.sub.6) .delta.: 13.31 (d, J = 1.1 Hz, 1H),
12.44 (s, 1H), 10.74 (s, 1H), 8.81 (s, 1H), 8.19 (d, J = 5.4 Hz,
1H), 8.10 (d, J = 1.8 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.42 (d, J
= 5.4 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 5.4 Hz, 1H),
7.02-7.00 (m, 1H), 6.97 (d, J = 2.3 Hz, 1H), 1.40 (s, 9H) 2 310.3
2.78 .sup.1H NMR (DMSO-d.sub.6) .delta.: 13.28 (d, J = 6.2 Hz, 1H),
11.79 (s, 1H), 9.20 (s, 1H), 8.80-8.78 (m, 1H), 8.19 (d, J = 5.4
Hz, 1H), 7.41 (d, J = 5.4 Hz, 1H), 7.16 (s, 1H), 7.08 (s, 1H), 1.36
(s, 18H) 3 366.1 1.71 4 310.3 2.75 .sup.1H NMR (DMSO-d.sub.6)
.delta.: 13.29 (s, 1H), 11.86 (s, 1H), 10.93 (s, 1H), 8.82 (d, J =
4.8 Hz, 1H), 8.19 (d, J = 5.4 Hz, 1H), 7.54 (d, J = 9.9 Hz, 2H),
7.42 (d, J = 5.4 Hz, 1H), 7.31 (t, J = 2.7 Hz, 1H), 6.39 (s, 1H),
1.44 (s, 9H) 5 399.5 1.89 6 361.3 1.68 .sup.1H NMR (DMSO-d.sub.6)
.delta.: 13.18 (d, J = 6.4 Hz, 1H), 12.44 (s, 1H), 10.74 (s, 1H),
8.67 (d, J = 6.3 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.85 (d, J =
1.1 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.03-6.97 (m, 2H), 2.41 (s,
3H), 1.40 (s, 9H) 7 366.1 1.51 .sup.1H NMR (DMSO-d.sub.6) .delta.:
13.17 (s, 1H), 12.48 (s, 1H), 11.51 (s, 1H), 8.68 (d, J = 4.9 Hz,
1H), 8.31 (s, 1H), 7.97 (s, 1H), 7.85 (d, J = 1.0 Hz, 1H), 7.51 (t,
J = 2.7 Hz, 1H), 6.59 (s, 1H), 2.41 (s, 3H) 8 361.3 1.68 .sup.1H
NMR (DMSO-d.sub.6) .delta.: 13.18 (d, J = 6.5 Hz, 1H), 12.48 (s,
1H), 10.72 (s, 1H), 8.72 (d, J = 6.3 Hz, 1H), 8.09 (d, J = 1.7 Hz,
1H), 7.65 (d, J = 8.6 Hz, 1H), 7.15 (d, J = 1.1 Hz, 1H), 7.01-6.97
(m, 2H), 2.63 (s, 3H), 1.39 (s, 9H) 9 380.2 1.71 10 392.2 1.64
.sup.1H NMR (400 MHz, DMSO) 13.17 (s, 1H), 12.48 (s, 1H), 11.51 (s,
1H), 8.68 (d, J = 4.9 Hz, 1H), 8.31 (s, 1H), 7.97 (s, 1H), 7.85 (d,
J = 1.0 Hz, 1H), 7.51 (t, J = 2.7 Hz, 1H), 6.59 (s, 1H), 2.41 (s,
3H) 11 380.2 1.74 H NMR (400 MHz, DMSO) 13.18 (d, J = 6.4 Hz, 1H),
12.44 (s, 1H), 10.74 (s, 1H), 8.67 (d, J = 6.3 Hz, 1H), 8.09 (d, J
= 1.7 Hz, 1H), 7.85 (d, J = 1.1 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H),
7.03-6.97 (m, 2H), 2.41 (s, 3H), 1.40 (s, 9H) 12 380.2 1.71 H NMR
(400 MHz, DMSO) 13.18 (d, J = 6.5 Hz, 1H), 12.48 (s, 1H), 10.72 (s,
1H), 8.72 (d, J = 6.3 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.65 (d, J
= 8.6 Hz, 1H), 7.15 (d, J = 1.1 Hz, 1H), 7.01-6.97 (m, 2H), 2.63
(s, 3H), 1.39 (s, 9H) 13 380.2 1.51 14 392 1.42
[0237] Assays for Detecting and Measuring .DELTA.F508-CFTR
Potentiation Properties of Compounds
[0238] Membrane Potential Optical Methods for Assaying
.DELTA.F508-CFTR Modulation Properties of Compounds
[0239] The optical membrane potential assay utilized
voltage-sensitive FRET sensors described by Gonzalez and Tsien (See
Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by
fluorescence resonance energy transfer in single cells" Biophys J
69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997)
"Improved indicators of cell membrane potential that use
fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in
combination with instrumentation for measuring fluorescence changes
such as the Voltage/Ion Probe Reader (VIPR) (See Gonzalez, J. E.,
K. Oades, et al. (1999) "Cell-based assays and instrumentation for
screening ion-channel targets" Drug Discov Today 4(9):
431-439).
[0240] These voltage sensitive assays are based on the change in
fluorescence resonant energy transfer (FRET) between the
membrane-soluble, voltage-sensitive dye, DiSBAC.sub.2(3), and a
fluorescent phospholipid, CC2-DMPE, which is attached to the outer
leaflet of the plasma membrane and acts as a FRET donor. Changes in
membrane potential (V.sub.m) cause the negatively charged
DiSBAC.sub.2(3) to redistribute across the plasma membrane and the
amount of energy transfer from CC2-DMPE changes accordingly. The
changes in fluorescence emission were monitored using VIPR.TM. II,
which is an integrated liquid handler and fluorescent detector
designed to conduct cell-based screens in 96- or 384-well
microtiter plates.
[0241] Identification of Potentiator Compounds
[0242] Typical protocol utilized a basolateral to apical membrane
Cl.sup.- concentration gradient. To set up this gradient, normal
ringers was used on the basolateral membrane and was permeabilized
with nystatin (360 .mu.g/ml), whereas apical NaCl was replaced by
equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a
large Cl.sup.- concentration gradient across the epithelium. All
experiments were performed 30 min after nystatin permeabilization.
Forskolin (10 .mu.M) and all test compounds were added to both
sides of the cell culture inserts. The efficacy of the putative
.DELTA.F508-CFTR potentiators was compared to that of the known
potentiator, genistein.
[0243] Solutions [0244] Basolateral solution (in mM): NaCl (135),
CaCl.sub.2 (1.2), MgCl.sub.2 (1.2), K.sub.2HPO.sub.4 (2.4),
KHPO.sub.4 (0.6), N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid (HEPES) (10), and dextrose (10). The solution was titrated to
pH 7.4 with NaOH. [0245] Apical solution (in mM): Same as
basolateral solution with NaCl replaced with Na Gluconate
(135).
[0246] Cell Culture
[0247] Fisher rat epithelial (FRT) cells expressing
.DELTA.F508-CFTR (FRT.DELTA..sup.F508-CFTR) were used for Ussing
chamber experiments for the putative .DELTA.F508-CFTR modulators
identified from our optical assays. The cells were cultured on
Costar Snapwell cell culture inserts and cultured for five days at
37.degree. C. and 5% CO.sub.2 in Coon's modified Ham's F-12 medium
supplemented with 5% fetal calf serum, 100 U/ml penicillin, and 100
.mu.g/ml streptomycin. Prior to use for characterizing the
potentiator activity of compounds, the cells were incubated at
27.degree. C. for 16-48 hrs to correct for the .DELTA.F508-CFTR. To
determine the activity of corrections compounds, the cells were
incubated at 27.degree. C. or 37.degree. C. with and without the
compounds for 24 hours.
[0248] 2. Whole-Cell Recordings
[0249] The macroscopic .DELTA.F508-CFTR current (I.sub..DELTA.F508)
in temperature- and test compound-corrected NIH3T3 cells stably
expressing .DELTA.F508-CFTR were monitored using the
perforated-patch, whole-cell recording. Briefly, voltage-clamp
recordings of I.sub..DELTA.F508 were performed at room temperature
using an Axopatch 200B patch-clamp amplifier (Axon Instruments
Inc., Foster City, Calif.). All recordings were acquired at a
sampling frequency of 10 kHz and low-pass filtered at 1 kHz.
Pipettes had a resistance of 5-6 M.OMEGA. when filled with the
intracellular solution. Under these recording conditions, the
calculated reversal potential for Cl.sup.-(E.sub.C1) at room
temperature was -28 mV. All recordings had a seal resistance >20
G.OMEGA. and a series resistance <15 M.OMEGA.. Pulse generation,
data acquisition, and analysis were performed using a PC equipped
with a Digidata 1320 A/D interface in conjunction with Clampex 8
(Axon Instruments Inc.). The bath contained <250 .mu.l of saline
and was continuously perifused at a rate of 2 ml/min using a
gravity-driven perfusion system.
[0250] Compounds exemplified herein exhibit activity in the assays
described hereinabove.
* * * * *
References